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ABSTRACT 
 
Transcription elongation regulator 1 (TCERG1) is a nuclear protein involved in 
transcriptional elongation and splicing events, suggesting these two activities may be 
connected.  Moreover, TCERG1 was recently identified as a novel interactor and co-repressor 
of CCAAT/Enhancer Binding Protein ! (C/EBP!) transcriptional
 
activity, suggesting TCERG1 
has additional biological roles.  Interestingly, TCERG1 also inhibits the growth arrest
 
activity 
of C/EBP!.  Additionally, the original clone found to interact with C/EBP! consisted of only 
the amino-terminal domain of TCERG1 and functional analysis of this clone indicated that it 
retained the ability to repress both C/EBP!-mediated growth arrest and transcriptional activity.  
Furthermore, a TCERG1 mutant whose amino-terminal region was deleted was unable to 
interact with or repress the transcriptional and growth arrest activities of C/EBP!, suggesting 
the functional domain(s) lie elsewhere.  In this study, domains of
 
TCERG1 were examined for 
the ability to inhibit C/EBP!-mediated growth arrest and
 
the mechanism whereby this effect 
occurs.  By exploiting fluorescent properties of expressed proteins fused with green fluorescent 
protein, the extent to which each TCERG1 mutant was able to reverse C/EBP!-mediated 
growth arrest of cultured cells was assessed.  Our
 
analyses suggest that the inhibitory
 
activity of 
TCERG1 lies within the amino-terminal region and may involve WWI and WWII domains 
within this region.  Additionally, laser scanning
 
confocal microscopy (LCSM) was used to 
visualize the subnuclear localization
 
of fluorescent proteins fused to TCERG1 and C/EBP!.  
When expressed alone, TCERG1 localized to splicing factor-rich nuclear speckles while 
C/EBP! was found to reside in discrete punctate foci, both localization patterns being distinct 
and different from each other.  Results from co-localization studies after co-expressing both 
proteins indicate an alteration in the subnuclear distribution of TCERG1.  Furthermore, 
TCERG1 co-localizes with C/EBP!,
 
suggesting a possible mechanism whereby TCERG1 
inhibits the growth arrest and transcriptional activities mediated by C/EBP!. 
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1.  INTRODUCTION AND OVERVIEW 
 
 The biological roles of transcription factors and the genes that they regulate have been a 
long-term focus for many researchers.  In particular, CCAAT/Enhancer Binding Protein ! 
(C/EBP!) has been studied extensively in its relation to two distinct activities mediated by 
different domains: transcriptional and anti-proliferative activity (Lekstrom-Himes and 
Xanthopoulos, 1998; Harris et al., 2001; Wang et al., 2001).  Although C/EBP! is characterized 
as a master regulator of several important tissue-specific genes, how this activity is achieved in 
addition to the regulation of its anti-proliferative effects has been a subject of debate for many 
years (reviewed in Darlington et al., 1995; Johnson, 2005).  Hence, McFie et al. (2006), sought 
to identify a potential co-factor and/or regulator of C/EBP! activity.  Using a yeast two-hybrid 
screening approach with a human liver cDNA library and the transactivation domain of 
C/EBP! (amino acids 6-217) as bait, a single novel interactor was identified as transcription 
elongation regulator 1 (TCERG1) (McFie et al., 2006).  TCERG1 was subsequently 
characterized for its role or function in relation to C/EBP! activity and the mechanism by 
which it occurs.  Although TCERG1 has been described as a negative-acting elongation factor 
that may bridge transcriptional and splicing events, most of the information gained from 
various studies is indirect and relies on conclusions based on other factors involved in these 
activities (Sune et al., 1997; Shimada et al., 1999; Sune and Garcia-Blanco, 1999; Bohne et al., 
2000; Carty et al., 2000; Goldstrohm et al., 2001; Smith et al., 2004; Pearson et al., 2008).  
Therefore, McFie et al. (2006) attempted to assign a biological role for TCERG1 in a way that 
could be directly linked to its function(s).  Using various biochemical techniques, results 
indicated that TCERG1 interacts with and acts as an inhibitor of C/EBP! transcriptional 
activity (McFie et al., 2006).  Chromatin immunoprecipitation analyses of mouse liver nuclei 
showed that TCERG1 was present with C/EBP! at gene promoters repressed by C/EBP!, such 
as hepatocyte nuclear factor-6, but not at promoters subject to C/EBP!-mediated 
transactivation, like the phosphoenolpyruvate carboxykinase promoter (McFie et al., 2006).  
This interesting result led to the proposal that TCERG1 may be involved in further repression 
of promoters down-regulated by C/EBP!.  Further characterization of TCERG1 revealed that it 
had no intrinsic repressor activity since a Gal4-TCERG1 fusion was unable to repress 
transcriptional activation of a reporter gene under the control of an SV40 promoter linked to a 
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number of Gal4 DNA binding sites.  Thus, the inhibition of transcription by TCERG1 may be 
specific to promoters responsive to C/EBP! transcriptional activity. 
 TCERG1 function was next examined in the context of C/EBP!-mediated growth arrest 
of cultured cells.  Previous studies showed that a short domain, consisting of amino acids 175-
217 in the amino terminus of C/EBP!, is involved in mediating the anti-proliferative activity of 
C/EBP! (Hendricks-Taylor and Darlington, 1995; Wang et al., 2001).  This region alone is able 
to inhibit cellular proliferation of cultured cells by inhibiting the activities of regulators of cell 
cycle progression, cyclin-dependent kinase (cdk) 2 and cdk4 (Wang et al., 2001).  In a recent 
study, researchers were able to show that upon overexpression of TCERG1, cellular arrest 
caused by C/EBP! is relieved (McFie et al., 2006).  Moreover, the amino-terminal domain of 
TCERG1 was sufficient to inhibit C/EBP! activity, suggesting that important functional 
domains required for the reversal of growth arrest are located in this region.  Further analysis by 
chromatin immunoprecipitation demonstrated that the amino-terminal region of TCERG1 
retained the ability to interact with C/EBP!. 
Despite the recent evidence gathered by McFie et al. (2006), it is still not understood 
which motifs of TCERG1 are implicated in the inhibitory activities of C/EBP! and the 
mechanism whereby this inhibition occurs.  The focus of my studies was to determine which 
functional domain(s) of TCERG1 are involved in the inhibition of cellular proliferation 
mediated by C/EBP! and to propose a model for the mechanism by which this occurs. 
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2.  REVIEW OF THE LITERATURE 
 
 
2.1  CCAAT/Enhancer Binding Protein Family 
 
 CCAAT/Enhancer Binding Proteins (C/EBPs) belong to a class of transcription factors 
that function as master regulators of several cellular responses (reviewed in Lekstrom-Himes 
and Xanthopoulos, 1998; Ramji and Foka, 2002).  To date, six isoforms have been identified: 
C/EBP!, -", -#, -$, -%, and -&, each designated by the Greek letter for the order in which each 
was discovered (Cao et al., 1991; Ramji and Foka, 2002).  Some c/ebp genes give rise to 
several transcripts due to differential splicing and others produce polypeptides of different sizes 
as a result of translation from alternative AUG start sites (Ramji and Foka, 2002).  C/EBPs bind 
to the DNA consensus sequence: RTTGCGYAAY, where R is A or G and Y is C or T, 
although variations of this motif have been identified (Osada et al., 1996).  All C/EBP isoforms 
share significant conservation, >90% identity, in the amino acid sequence found in the carboxy-
terminal domain.  This domain consists of two important functional regions collectively termed 
the bZIP domain: a basic amino acid-rich region responsible for DNA binding and a leucine 
zipper motif that is involved in dimerization with other C/EBP molecules.  Dimerization 
between two C/EBP molecules via the leucine zipper is a prerequisite for DNA binding (Agre 
et al., 1989).  C/EBPs can form homo- and heterodimers with other C/EBPs or bZIP proteins 
depending on the type of tissue and cellular state as expression of C/EBPs may be altered 
during certain physiological conditions.  Heptad repeats consisting of leucine and other 
hydrophobic residues in the leucine zipper region form an !-helical arrangement through 
interactions with a second heptad repeat, generating a coiled-coil structure in parallel 
orientation (Landschulz et al., 1988b; Vinson et al., 1993; Podust et al., 2001).  The resulting 
dimer forms a helical structure resembling a pair of scissors, each blade representing the basic 
region from each monomer, which becomes associated with the DNA binding consensus 
sequence found in the DNA major groove (Podust et al., 2001; Tahirov et al., 2001).  In 
general, the amino-terminal domain of all C/EBPs is divergent but some share components of 
the transactivation domains (TAD) found within this region.  C/EBP# and C/EBP" liver 
inhibitor protein (LIP) isoform lack a TAD, and thus form non-functional heterodimers that can 
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bind to DNA but are incapable of transcriptional activity (Descombes and Schibler, 1991).  
C/EBP& also acts as an inhibitor due to the presence of proline residues in the basic region that 
lead to the disruption of the !-helical arrangement; thus heterodimers can no longer bind to the 
DNA consensus sequence (Ron and Habener, 1992).  Taken together, the majority of C/EBPs 
function to activate specific genes in a variety of cellular responses and tissues, while others 
function to repress or inhibit transcriptional activity by forming inactive heterodimers with 
other C/EBP isoforms. 
 C/EBPs participate in the regulation of a variety of biological functions involving the 
expression of hormones, mitogens, cytokines, nutrients and toxins, amongst many others 
(Darlington et al., 1995; Lekstrom-Himes and Xanthopoulos, 1998; Roesler, 2001; Ramji and 
Foka, 2002).  Additionally, some non-transcriptional roles exerted by C/EBPs involve cellular 
proliferation, differentiation and inflammation response (reviewed in Lekstrom-Himes and 
Xanthopoulos, 1998; Ramji and Foka, 2002).  Many of the responses elicited by C/EBPs are 
dependent on the state of the cell and the tissue in which this activity occurs.  For example, 
several C/EBP members are involved in the differentiation process of several tissues including 
hepatocytes and adipocytes, which have been studied most extensively (Christy et al., 1989; 
Cao et al., 1991; Mischoulon et al., 1992; Darlington et al., 1998).  When cells are subjected to 
hormone stimulation, expression of C/EBP" and -$ are induced first, then activate transcription 
of c/ebp! later during the differentiation process (Cao et al., 1991; Christy et al., 1991; Umek et 
al., 1991; Mischoulon et al., 1992; Legraverend et al., 1993).  As levels of C/EBP! rise 
significantly, it acts as a master regulator of tissue-specific genes possessing C/EBP binding 
sites in their promoter regions (MacDougald et al., 1995).  Elegant studies by several groups of 
researchers have shown that C/EBP! alone is both required and sufficient to trigger 
differentiation of pre-adipocytes even in the absence of stimulants for differentiation initiation 
(Samuelsson et al., 1991; Freytag and Geddes, 1992; Freytag et al., 1994; Lin and Lane, 1994; 
Lane et al., 1996).  Collectively, these studies and others used a variety of techniques to show 
that induction of C/EBP! is adequate to promote differentiation of several cell types (Freytag et 
al., 1994; Lin and Lane, 1994).  Finally, terminal differentiation and maintenance of quiescence 
is thought to be largely under the control of C/EBP! (Christy et al., 1989; Mischoulon et al., 
1992; Legraverend et al., 1993; Lane et al., 1996; Jiang and Lane, 2000).  The main C/EBP 
isoform under investigation in this thesis is C/EBP! and is discussed in more detail below. 
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2.1.1  Structure and Biological Roles of C/EBP! 
 
 C/EBP!, which consists of 358 amino acids, was the first C/EBP family member to be 
cloned, and has since been extensively characterized (Figure 1) (Landschulz et al., 1988a; 
Birkenmeier et al., 1989; Cao et al., 1991; Darlington et al., 1995, 1998; Lekstrom-Himes and 
Xanthopoulos, 1998; Gheorghiu et al., 2001; Roesler, 2001).  C/EBP! was originally identified 
as a heat-stable factor found in rat liver nuclei that interacted with the CCAAT-box motif found 
upstream of several viral promoters in addition to core homology enhancer regions (Landschulz 
et al., 1988a).  Like all C/EBP transcription factors, C/EBP! contains a highly conserved 
carboxy-terminal basic region and leucine-zipper motif, collectively termed the bZIP domain, 
that is involved in dimerization and DNA binding (Figure 1) (Landschulz et al., 1988a, 1988b).  
Expression of C/EBP! occurs in a variety of tissues such as adipose, liver, intestine, lung, 
adrenal gland, peripheral-blood mononuclear cells and placenta tissues, with the highest levels 
of expression present in the differentiated cells of adipose and liver tissue (Antonson and 
Xanthopoulos, 1995).  The translation of the mRNA encoding C/EBP! generates two 
polypeptides of 30 and 42 kDa, p30
C/EBP!
 and p42
C/EBP!
, respectively, due to alternate AUG 
translational start sites, with the former having lower transactivation potential (Ossipow et al., 
1993).  Much of what is known about the biological importance of C/EBP! was discovered 
using murine knock-out models (Darlington et al., 1995; Wang et al., 1995).  Analyses of 
c/ebp!
-/-
 knock-out mice appear phenotypically normal at birth but die soon after from severe 
hypoglycemia (Darlington et al., 1995).  In addition, within the first two hours after birth, 
glycogen stores are not detected due to the drastic reduction in glycogen synthase activity and 
mRNA levels of key gluconeogenic enzymes.  Thus, no glucose can be synthesized from 
hepatic stores or be maintained at normal levels in the blood.  C/EBP!-deficient mice also have 
greatly reduced lipid stores in the form of white and brown adipose tissue.  Collectively, these 
studies presented by Darlington et al. (1995) using c/ebp!
-/-
 knock-out mice have contributed 
greatly to our understanding of the vital roles C/EBP! plays in post-natal development, 
metabolic processes and the transcriptional regulation of genes which it governs. 
Extensive studies have revealed that C/EBP! is a very important nuclear protein with 
two distinct activities mediated by different domains (Lekstrom-Himes and Xanthopoulos, 
1998; Harris et al., 2001; Wang et al., 2001).  The transcriptional activity of C/EBP! occurs
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Figure 1.  CCAAT/Enhancer-Binding Protein ! (C/EBP!) is a Transcription Factor with 
Two Distinct and Separate Functions. 
C/EBP! consists of 358 amino acids and functions as a transcription factor by first forming 
dimers through the leucine zipper, followed by DNA binding mediated by the basic region and 
leucine zipper (collectively, bZIP).  Subsequently, C/EBP! regulates transcriptional activity via 
transactivation elements found within the first 200 residues, which makes up the transactivation 
domain (TAD).  C/EBP! also functions to inhibit cellular proliferation by interacting with 
proteins critical for cell cycle progression through the growth inhibitory region (GIR; amino 
acids 175-217). 
 
 
 
through C/EBP-dependent dimerization and DNA binding via the bZIP domain, and 
subsequently operates to activate and repress many important and tissue-specific genes 
(reviewed in Darlington et al., 1995; Lekstrom-Himes and Xanthopoulos, 1998; Roesler, 2001; 
Ramji and Foka, 2002).  The second function of C/EBP! involves cellular growth arrest and 
differentiation of certain cell types.  This activity was first suggested by Umek et al. (1991), to 
involve the amino-terminal domain of C/EBP!.  Since then, a short region spanning amino 
acids 175-217 within the amino terminus has been identified and termed the growth inhibitory 
region (GIR, Figure 1) (Hendricks-Taylor and Darlington, 1995; Wang et al., 2001).  In a study 
presented by Wang et al. (2001), results from in vitro glutathione-S-transferase-pulldown 
assays and later confirmed by in vivo assays, showed that critical components for cell cycle 
progression, cdk2 and cdk4, bind to a short region found within the GIR of C/EBP!.  This 
interaction occurs via the kinase activity domains of each cdk, thereby preventing association 
with their respective cyclins.  Finally, Wang et al. (2001) examined a variety of cultured cells 
for transcriptional targets regulated by C/EBP! in a growth arrest-dependent manner, but none 
were identified.  This suggests that the transcriptional activity of C/EBP! is not required for 
inhibiting cellular proliferation and that C/EBP!-mediated growth arrest and transcriptional 
activity can operate independently of each other. 
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2.1.1.1  Mechanism and Regulation of C/EBP! Transcriptional Activity 
 
C/EBP! is a transcription factor that is involved in the regulation of tissue-specific 
genes that play critical roles in energy metabolism (reviewed in Darlington et al., 1995; 
Roesler, 2001).  Transcriptional activity occurs via three transactivation elements (TE I-III) 
located within the first 200 residues of the amino-terminal region (Figure 1) (Friedman et al., 
1989).  TE I and II interact with components of the basal RNA polymerase II (RNAPII) 
transcriptional machinery, TATA-binding protein (TBP) and TFIIB, to mediate transactivation 
(Nerlov and Ziff, 1995).  However, TE III has been characterized as a negative regulatory 
domain (Nerlov and Ziff, 1994). 
Several co-activators of C/EBP! transcriptional activity have been identified.  These 
include p300/CREB-binding protein (CBP) histone acetyltransferases, TBP and retinoblastoma 
tumor-suppressor protein (Rb) (Chen et al., 1996; Erickson et al., 2001; Wang and Timchenko, 
2005).  These two co-activators bind to regions found in the TE I region of C/EBP! and 
enhance the DNA binding and transactivation potential of C/EBP! (Chen et al., 1996; Charles 
et al., 2001; Erickson et al., 2001).  C/EBP! can also recruit the chromatin remodeling complex 
SWItch/Sucrose Non-Fermentable (SWI/SNF) to the proximity of the promoter region by 
interacting with the Brahma (Brm) subunit of this complex (Pedersen et al., 2001; Muller et al., 
2004).  Recent evidence suggests that sumoylation may be involved in the regulation of 
C/EBP! activity (Khanna-Gupta, 2008).  Sumoylation of lysine 159 found in the TE III 
negative regulatory region of C/EBP! has been implicated in the decreased ability of C/EBP! 
to transactivate liver- and myeloid-specific genes.  Moreover, reporter assays conducted in 
erythroleukemia cells demonstrate that overexpression of p30
C/EBP!
 causes increased 
sumoylation of p42
C/EBP!
, thereby inhibiting its transcriptional activity.  Finally, downregulation 
of C/EBP! occurs in cells stimulated with insulin or epidermal growth factor, which leads to an 
increased turnover rate of C/EBP! transcripts (Christy et al., 1991; Samuelsson et al., 1991; 
Mischoulon et al., 1992; Legraverend et al., 1993; MacDougald et al., 1995; Lane et al., 1996).  
Thus, by altering C/EBP! mRNA levels, the rate of transcription is affected, leading to lower 
levels of C/EBP! expression.  Insulin also affects the regulation of C/EBP! by indirectly 
activating serine/threonine protein phosphatase 1 and 2A, which dephosphorylate C/EBP!, 
abrogating its DNA-binding activity (MacDougald et al., 1995). 
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2.1.1.2  Regulation of C/EBP! Growth Arrest Activity and Differentiation 
 
A very different but no less important role for C/EBP! involves differentiation of 
several cell types and the process of cellular regeneration (Birkenmeier et al., 1989; Christy et 
al., 1991; Ramji and Foka, 2002).  In the late 1980’s, scientists showed that C/EBP! was 
expressed in the tissues of adult livers and was found exclusively in differentiated hepatocytes 
and adipoctyes (Birkenmeier et al., 1989; Friedman et al., 1989).  In 1991, C/EBP! function 
was first related to cellular growth arrest and terminal differentiation of pre-adipocytes (Christy 
et al., 1991; Samuelsson et al., 1991; Umek et al., 1991).  Since then, several lines of evidence 
from studies in several cell types have suggested that C/EBP! function has an inverse 
relationship to cellular proliferation and mitotic clonal expansion (Ramji and Foka, 2002; 
Johnson, 2005).  For example, C/EBP! is extensively linked to the regeneration of liver tissue 
after a partial hepatectomy, whereby 60-70% of hepatic tissue is surgically removed 
(Mischoulon et al., 1992; Flodby et al., 1996).  Under these conditions, differentiated cells 
acquire the ability to re-enter the cell cycle by undergoing a reorganization of the regulatory 
mechanisms involved in the maintenance of cellular fate.  This process involves the temporal 
expression of specific factors required to initiate this process (Mischoulon et al., 1992; 
Greenbaum et al., 1995; Diehl, 1998).  In the first 24 hours after a partial hepatectomy, the 
abundance of C/EBP family members -" and -$ mRNA levels increase and cyclin D, a cell 
cycle regulatory factor, is induced (Mischoulon et al., 1992; Greenbaum et al., 1995; Wang et 
al., 2001).  Subsequently, DNA binding of C/EBP" and -$ to the promoter region of c/ebp! is 
enhanced, resulting in the upregulation of C/EBP! expression.  Once expressed, C/EBP! 
regulates its own expression in order to maintain the terminally differentiated state of the cell 
(Christy et al., 1991; Mischoulon et al., 1992; Legraverend et al., 1993; MacDougald et al., 
1995; Timchenko et al., 1995).  Regulation of the expression of C/EBP! by itself was 
demonstrated in an elegant study by Lin and Lane (1994).  In this study, a missense mutation 
was introduced into the c/ebp! gene such that the translational start site for the 30 kDa isoform 
was eliminated, thus only p42
C/EBP!
 could be expressed.  Upon the expression of the mutated 
C/EBP! in cells, subsequent levels of endogenous p30
C/EBP!
 and p42
C/EBP!
 transcripts could be 
detected regardless of differentiation status, suggesting that C/EBP! is involved in the 
regulation of its own expression.  Moreover, when cells were stimulated to differentiate, the 
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onset of endogenous C/EBP! expression occurred one day later compared to cells 
overexpressing C/EBP! and induced to differentiate concurrently.  The extent of the 
involvement of C/EBP! in the maintenance of the differentiated state was demonstrated in 
C/EBP!
-/-
 livers, which have increased proliferation rate (Flodby et al., 1996).  Moreover, 
Wang et al. (1995) showed that transgenic mice containing null mutations in the c/ebp! gene 
display a dramatic increase in hepatocyte differentiation at birth.  The expression and regulation 
of C/EBP! occur in a similar manner in cultured pre-adipocytes under conditions where 
differentiation is stimulated (Christy et al., 1989, 1991; Cao et al., 1991).  The sequence of 
events that drive cells into the process of and maintenance of either proliferation or 
differentiation is complex and involves many levels of regulation.  It is often found that many 
of the factors involved in these events play reciprocal roles between the different cellular fates, 
enhancing the expression of some genes, while repressing others.  Although it has been well 
established that several C/EBP isoforms are involved in the maintenance of terminally 
differentiated quiescent cells, the intricacies involved in the entire process still remain to be 
fully elucidated. 
It has been established that C/EBP! can inhibit the proliferation of a variety of tissues 
and cultured cells (Wang et al., 2001; Johnson, 2005; McFie et al., 2006).  Several different 
models have been proposed for the mechanism of growth arrest depending on the state of the 
cell and tissue in which it occurs (Figure 2) (Johnson, 2005; Wang and Timchenko, 2005; 
Wang et al., 2006).  C/EBP! can interact with many components important for cell cycle 
progression in each model including cdk2, cdk4, E2F transcription factor, Rb, and the Brm 
subunit of the SWI/SNF chromatin remodeling complex (Timchenko et al., 1997, 1999b; 
Pedersen et al., 2001; Porse et al., 2001; Wang et al., 2001, 2002a, 2004; Iakova et al., 2003; 
Muller et al., 2004).  For example, in early to mid-G1 phase, growth arrest occurs because of 
C/EBP!-mediated induction of the cdk inhibitor p21 expression, leading to the formation of 
stable p21/C/EBP! complexes (Figure 2 upper left, green arrow).  This in turn causes the 
inhibition of cdk/cyclin kinase activity that normally functions to disrupt Rb/E2f inhibitory 
complexes (Timchenko et al., 1996, 1999a, 1999b).  Thus, E2F remains bound to Rb and is 
unable to bind to the promoter regions of S-phase specific genes and activate transcription.  
Alternatively, C/EBP! interacts with the kinase activity domains of cdk2 and cdk4, resulting in 
the inhibition of their kinase activity (Figure 2 upper left, red blocked arrow) (Wang et al., 
 10 
 
 
 
 
 
 
Figure 2.  Model for C/EBP!-Mediated Growth Arrest. 
C/EBP!-mediated growth arrest occurs as a result of one or more different levels of regulatory 
activity depending on the stage of the cell cycle.  In G1, cyclin-dependent activation of cdk4/6 
and later cdk2 leads to the phosphorylation of Rb (blue arrows, upper left).  This results in its 
dissociation from transcription factor E2F, which is important for the transcriptional regulation 
of S-phase genes.  Alternatively, C/EBP! may also cause growth arrest by direct interactions 
with cell cycle regulators or by affecting the transcriptional activity of cell cycle-specific genes 
at promoter sites.  C/EBP! can act through p21, which itself inhibits the activities of cdks, or by 
direct binding to cdk2 and cdk4 in G1 phase.  C/EBP! may also be recruited to E2F-dependent 
promoters via interactions with E2F and/or histone deacetylase/SWI/SNF chromatin 
remodeling complex or by directly binding to E2F sites in the promoter region leading to 
transcriptional inhibition of S-phase genes (right side).  This image has been modified from 
Johnson, 2005 and based on evidence provided or reviewed by Timchenko et al., 1999a, 1999b; 
Slomiany et al., 2000; Pedersen et al., 2001; Porse et al., 2001; Wang et al., 2001, 2006; Muller 
et al., 2004; Wang and Timchenko, 2005. 
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2001).  Studies show that a C/EBP! mutant unable to inhibit cdk2 cannot cause growth arrest, 
but mutants defective in DNA binding still retain anti-proliferative activity, suggesting that the 
first mechanism of growth arrest may be a compensatory tool in conditions where DNA binding 
of C/EBP! is altered (Harris et al., 2001).  In a third scenario, when cells approach S-phase, 
C/EBP! acquires the ability to interact with and recruit the SWI/SNF chromatin remodeling 
complex and histone deacetylases to promoter sites regulated in an E2F-dependent manner 
(Figure 2 upper right) (Slomiany et al., 2000; Pedersen et al., 2001; Porse et al., 2001; Iakova et 
al., 2003).  Once localized to the promoter region, C/EBP! associates with E2F, thereby 
inhibiting E2F-mediated transcriptional activation.  This type of regulation has been observed 
in adipose tissue (Dyson, 1998).  However, evidence from a different study implicates the 
second model of growth arrest by the inhibition of cdk2/cyclin complexes through interactions 
with C/EBP! as the main mechanism of growth arrest in the liver (Wang et al., 2001).  This 
demonstrates that several mechanisms of C/EBP! anti-proliferative effects exist and may be 
specific to certain tissue types.  Finally, studies have also shown that C/EBP! can bind to 
promoter regions containing E2F binding sites such as the dihydrofolate reductase promoter in 
the absence of E2F (Figure 2 lower right) (Slomiany et al., 2000; Harris et al., 2001; Wang and 
Timchenko, 2005).  This type of transrepression mediated by C/EBP! has been proposed as the 
mechanism for the inhibition of hepatocyte proliferation in livers of old mice (Wang et al., 
2006). 
It can be challenging to examine the mechanisms of C/EBP! anti-proliferative activity 
since even low levels of C/EBP! expression results in growth arrest and can lead to apoptosis 
(McFie et al., 2006, my observations).  However, sumoylation of Lys159 in the TE III has been 
shown to block the growth arrest activity of C/EBP! by preventing interactions with critical 
subunits of the SWI/SNF chromatin remodeling complex important for regulating E2F-
dependent genes (Khanna-Gupta, 2008).  Similar inhibition of C/EBP! has been observed when 
serine 193 is dephosphorylated, a process which occurs after cells have been stimulated with 
insulin (Wang and Timchenko, 2005).  These results were confirmed when Ser193 was 
replaced with threonine, which cannot be phosphorylated by the specific kinase activated from 
insulin-mediated stimulation.  Additionally, insulin inhibits C/EBP! activity by enhancing the 
turnover rate of C/EBP! mRNA, leading to the downregulation of C/EBP! expression and its 
activity (MacDougald et al., 1995). 
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2.2  Transcription Elongation Regulator 1 
 
2.2.1  Structure of TCERG1 
 
TCERG1, formally known as co-activator of 150 kDa or CA150, was first discovered as 
a nuclear protein involved in Tat-activated transcription of the human immunodeficiency virus-
1 long terminal repeat (HIV-1 LTR) promoter through interactions with Tat-specific factor 1 
(Sune et al., 1997).  TCERG1 is a large nuclear protein consisting of 1098 amino acids and is 
approximately 150 kDa (Figure 3).  A second variant of TCERG1 in humans also exists that is 
missing 21 internal residues due to the excision of an in-frame exon resulting in a protein of 
1077 amino acids in length.  However, the full-length form that has been the subject of most 
studies.  Highly conserved across species from C. elegans to H. sapiens, TCERG1 is also 
expressed in all human tissues albeit at different levels (Bohne et al., 2000).  Several studies 
examining the role of TCERG1 in brain tissue, where it is highly expressed, have suggested an 
involvement in Huntington’s disease pathogenesis (Holbert et al., 2001; Chattopadhyay et al., 
2003; Arango et al., 2006).  The amino-terminal domain of TCERG1 contains three WW 
domains that each consists of 20-23 residues, containing several aromatic amino acids flanked 
by conserved tryptophan residues (WW) (Figure 3).  These domains are involved in protein-
protein interactions with proline-containing sequences found in proteins such as splicing factor-
1 (Goldstrohm et al., 2001).  In addition, the amino-terminal domain contains a glutamine-
alanine (QA)-repeat, unique among mammalian proteins, but whose function is currently 
unknown, and a putative nuclear localization signal (NLS).  The carboxy terminus of TCERG1 
includes six FF domains, in which two conserved phenylalanine (FF) residues are separated by 
~35 amino acids, that also mediate protein-protein interactions.  These modules have been 
shown to bind the phosphorylated carboxy-terminal repeat domain (CTD) of RNAPII through 
weak interactions contributed by multiple FF domains of TCERG1 (Sune et al., 1997; Carty et 
al., 2000).  Several lines of evidence have suggested that interactions provided by the FF and 
WW domains of TCERG1 act as a bridge between negative regulation of transcriptional 
elongation and pre-mRNA splicing events, respectively (Carty et al., 2000; Goldstrohm et al., 
2001; Lin et al., 2004; Smith et al., 2004). 
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Figure 3.  Transcription Elongation Regulator 1 (TCERG1) is a Constitutively Expressed 
Nuclear Protein of 150 kDa. 
TCERG1 consists of 1098 amino acids with several functional domains.  In the amino terminal 
domain lie three domains (purple) that each consist of 23 amino acids flanked by tryptophan 
residues that bind to proline-rich sequences, termed WW domains (purple).  In addition, there is 
a unique glutamine-alanine repeat (QA, teal) with no known functional role.  A putative nuclear 
localization signal (NLS, red) lies between the amino and carboxy terminal domains.  The 
carboxy terminal region contains six FF domains designated by sequences of amino acids 
flanked by phenylalanine residues that are also involved in protein-protein interactions. 
 
 
2.2.2  Functional Roles of TCERG1 
 
Currently, the functional characterization of TCERG1 is focused on its role in 
transcriptional and elongation events.  TCERG1 regulates transcription of HIV-1 LTR in part 
by affecting elongation efficiency of RNAPII complexes (Sune and Garcia-Blanco, 1999).  This 
conclusion was supported by the results obtained from a collection of experiments.  First, 
ectopic expression of TCERG1 represses HIV-1 LTR basal and Tat-activated transcription in 
vivo and is dependent on the presence of a TATA-box.  Moreover, this activity is specific to the 
TATA-box of HIV-1 LTR and not other viral promoters such as CMV, early SV40, RSV, or 
HSVTK.  However, transrepression by TCERG1 can be inhibited in the presence of high levels 
of transcription factor TBP, although the mechanism of inhibition is indirect since TBP neither 
interacts with nor alters the levels of TCERG1 expression.  Second, using an RT-PCR based 
assay to quantify the production of short and long transcripts, overexpression of TCERG1 
resulted in a marked 5-fold decrease in the amount of long transcripts in comparison to short 
transcripts.  Collectively, these results lead Sune and Garcia-Blanco (1999) to propose that 
TCERG1 forms complexes with unidentified components of a negative-acting elongation 
complex, causing inefficient elongation of transcripts.  Hence, it is unknown if TCERG1 affects 
RNAPII directly or during the formation of an elongation-competent RNAPII complex.  If the 
latter is true, then TCERG1 may interact with this complex, leading to a disruption of the 
RNAPII holoenzyme or critical components associated with it.  In fact, Carty et al. (2000) were 
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able to show by Far-Western analysis that TCERG1 binds to the phospho-CTD of RNAPII 
which is competent for elongation.  Moreover, TCERG1 exclusively binds to the 
hyperphosphorylated elongation form of RNAPII and not to its unphosphorylated counterpart, 
shown by co-immunoprecipitation analysis (Carty et al., 2000).  Findings presented by Sune et 
al. (1997) and Goldstrohm et al. (2001) demonstrated the ability of TCERG1 to associate with 
positive transcription elongation factor-b (PTEF-b), a nuclear protein whose major function is 
in elongation.  Collectively, these studies support the hypothesis that TCERG1 is involved in 
the downregulation of the elongation process of pre-mRNA production.  Finally, studies by 
Carty et al. led to the functional characterization of the FF domains in TCERG1.  Results of 
Far-Western analyses indicated that FF2 and FF5 were required for binding to phospho-CTD of 
RNAPII and were subsequently classified as protein binding domains (Carty et al., 2000). 
Since the identification of TCERG1, researchers have embarked on a quest to find a 
direct biological role for this elusive nuclear protein.  Results of in situ RNA analysis in mouse 
embryos showed that TCERG1 could be involved in limb development since elevated levels of 
TCERG1 were detected in zones with high mitotic activity in the appendages.  Additionally, 
other studies have provided strong evidence for a role for TCERG1 in Huntington’s disease 
based on the presence of high levels of TCERG1 in neuronal aggregates in the brain tissue of 
patients with this disease (Holbert et al., 2001).  Moreover, increased levels of TCERG1 and 
accumulation of aggregates correlates with the increase in grade of the disease, suggesting an 
underlying function in Huntington’s disease pathogenesis (Holbert et al., 2001).  Finally, McFie 
et al. (2006) has recently discovered a new biological role for TCERG1 with respect to the 
inhibition of C/EBP!-mediated transcriptional and growth arrest activity.  The exploration into 
the regulation of C/EBP! activity mediated by TCERG1 thus far is discussed below and forms 
the foundation from which my thesis is based. 
 
2.2.3  TCERG1 Acts as an Inhibitor of C/EBP! Activity 
 
Recently, McFie et al. (2006) used a yeast two-hybrid approach to identify novel 
interacting co-factors of C/EBP! using a C/EBP! molecule consisting of amino acids 6-217.  
Furthermore, the mutated C/EBP! transcriptional activity was inactivated by the introduction of 
three point mutations in order to decrease the potential background transcriptional activation 
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mediated by this domain.  Upon screening of a human liver cDNA library, one clone was 
isolated and identified as TCERG1.  Additional experiments, such as chromatin 
immunoprecipitation assays, gave further evidence to support the interaction between these two 
proteins.  Furthermore, yeast two-hybrid analysis demonstrated a strong genetic interaction 
between these two proteins.  TCERG1 and another C/EBP isoform, C/EBP", were also shown 
to interact, suggesting TCERG1 may be able to function with other C/EBP molecules.  
Subsequently, reporter gene assays also showed that TCERG1 is able to repress the 
transactivation activities of C/EBP! and C/EBP" in a dose-dependent manner.  Moreover, 
TCERG1 demonstrated a dominant effect over the enhanced transactivation potential of 
C/EBP" in the presence of co-activator p300 by significantly inhibiting transcriptional activity. 
To investigate if TCERG1 was present on C/EBP!-specific promoter sites, chromatin 
immunoprecipitation analyses were used to examine two different types of promoters regulated 
by C/EBP!: one that is activated and one that is repressed by C/EBP!, the PEPCK and the 
hepatocyte nuclear factor-6 promoter, respectively (McFie et al., 2006).  Interestingly, 
TCERG1 was only detected at the hepatocyte nuclear factor-6 promoter repressed by C/EBP!, 
suggesting that TCERG1 was recruited to this promoter and may be involved in regulating 
C/EBP! transrepression of this promoter. 
TCERG1 was also assessed for any involvement in the growth arrest activity of 
C/EBP!.  When overexpressed, TCERG1 showed the remarkable ability to reverse the anti-
proliferative effects of C/EBP! in cultured cells (McFie et al., 2006).  Upon further 
examination, TCERG1 could neither interact with nor inhibit the growth arrest activities of a 
mutant containing only the GIR (amino acids 175-217, see Figure 1) of C/EBP!, suggesting the 
interaction and/or functional domain(s) lie elsewhere in C/EBP!.  Moreover, since the original 
clone obtained from the yeast two-hybrid screen contained amino acids 89-480 of the amino-
terminal domain of TCERG1, a truncation mutant consisting of amino acids 641-1098 of 
TCERG1 was constructed under the suspicion that the amino-terminal domain was involved in 
mediating inhibition of C/EBP! anti-proliferative activity.  This mutant did not interact with or 
act as a co-repressor of any C/EBP! activities relating to growth arrest or transcriptional 
activity, leading to the preliminary conclusion that the amino-terminal domain of TCERG1 
contained the important functional domains required for interaction with C/EBP! and for 
mediating its repressive effects on C/EBP! activity. 
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2.3  Subnuclear Compartmentalization 
 
 Recent evidence suggests that subnuclear localization is involved in the regulation of 
gene expression (Misteli et al., 1997; Matera, 1999; Mintz and Spector, 2000; Phair and 
Misteli, 2000; Hendzel et al., 2001; Misteli, 2001, 2007, 2008a; Carmo-Fonseca, 2002; Iborra 
and Cook, 2002; Wang et al., 2002b; Corry and Underhill, 2005; Gorski et al., 2006; Dernburg 
and Misteli, 2007).  Furthermore, the nucleus contains many functionally different non-
overlapping compartments that facilitate several different types of activity, including 
transcriptional and splicing events.  Data also suggest that the proteins involved in these 
processes are stored in one region within the nucleus and recruited to others where activities, 
such as transcriptional activity, occur.  Therefore, subnuclear localization may play a role in the 
inhibition of C/EBP! activity mediated by TCERG1. 
 
2.3.1  Characterization of Nuclear Bodies 
 
With the advent of new imaging technology, extensive research has been conducted in 
an effort to better understand the complexity of the nucleus (Iborra et al., 2003).  Several lines 
of evidence have revealed that the nucleus consists of various subcompartments that are 
arranged into distinct non-membranous domains, termed nuclear bodies or nuclear factories 
(reviewed in Matera, 1999; Misteli, 2001; Wang et al., 2002a).  Each range in size from 0.1 to 
several micrometers and are generally distinguished by their unique distribution pattern.  
Although most nuclear bodies have not been fully characterized, their constituents and the 
functional roles that accompany the different proteins they contain have generally defined each 
type of nuclear body.  Thus, assigning biological functions to each type of subnuclear structure 
has created a new area of research devoted to investigating the dynamic environment within the 
nucleus. 
It has been suggested that interactions between nuclear bodies and other foci are 
dynamic and can change in response to cellular signals and/or other factors (Matera, 1999; 
Wang et al., 2002b; Dernburg and Misteli, 2007).  Moreover, the establishment of nuclear 
architecture is critical for bringing nuclear factors and protein complexes within close 
proximity, permitting the coupling of events, such as transcription and pre-mRNA processing, 
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Figure 4.  Models of Nuclear Body Assembly. 
A.  Nuclear bodies form by the association of its components in an ordered and sequential 
fashion.  Each new constituent becomes associated based on the nuclear factors already present.  
B.  Formation of nuclear bodies occurs by random assembly of related nuclear factors, thereby 
generating a concentration of nuclear factors.  This image has been modified from Misteli, 
2008a. 
 
 
or to segregate nuclear structures as a means of global regulation.  Two models have been 
proposed for the purpose of higher-ordered nuclear architecture (Figure 4) (Misteli, 2001, 2007, 
2008a; Kaiser et al., 2008).  One model suggests that the nucleus contains several 
compartmentalized structures that are formed in an ordered and sequential way, and serve as 
stable storage sites for various nuclear factors (Figure 4A) (Misteli, 2001, 2007, 2008a).  The 
second model proposes that nuclear bodies self-assemble through random associations of freely 
moving molecules (Figure 4B) (Misteli, 2001; Kaiser et al., 2008).  Furthermore, it has been 
proposed that the integrity of nuclear body stability may be influenced by several factors and 
the interactions between molecules are generally transient in nature.  Recently, an elegant study 
was published that followed the de novo formation of Cajal bodies, which contain various types 
of ribonucleoproteins (Kaiser et al., 2008).  In this study, the kinetics of Cajal body formation 
was measured by limiting the concentrations of proteins known to localize in these nuclear 
subcompartments.  Results suggest that the formation of Cajal bodies support the self-assembly 
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model.  However, assembly and establishment of other types of nuclear bodies may occur 
through an organized mechanism that involves pre-established subnuclear architecture.  
Regardless of the nuclear body formation mechanism, the formation event itself can be 
influenced by a number of factors including cellular signals, post-translational modification of 
its constituents, energy dependence, cell cycle regulation, or even in a tissue-specific manner 
(Matera, 1999; Misteli, 2001; Wang et al., 2001).  Moreover, the speed at which each molecule 
can diffuse unobstructed through the nucleoplasm in the presence of other nuclear bodies and 
chromatin structure and the strength with which each bind other components of the newly 
formed structure, contribute to the rate of nuclear body formation.  Collectively, nuclear bodies 
are thought to be highly dynamic in order to co-ordinate the flux of certain factors to and from 
sites of activity. 
 
2.3.2  Role of Nuclear Bodies in Gene Regulation 
 
The formation and stability of nuclear bodies have been described as dynamic events 
that involve rapid exchange of factors to either assemble functional stations or release 
components into the nucleoplasm so they may transverse to sites of activity (Gorski et al., 
2006; Misteli, 2007, 2008a).  Moreover, the establishment of subnuclear organization provides 
an efficient way to concentrate nuclear factors in a controlled environment that can be 
dedicated to a specific function (Hendzel et al., 2001). 
Although chromatin mobility in interphase nuclei is to some extent limited and its 
architecture is highly structured, chromatin can undergo re-organization in the proper 
conditions.  The accessibility and regulation of chromatin structure, often determined by the 
status of histone acetylation, provide the driving force for the subsequent efflux and assembly 
of regulatory protein complexes involved in the coordination of transcription and pre-mRNA 
splicing events.  The importance of chromatin structure in the formation and stability of 
subnuclear compartments is critical during interphase of the cell cycle in order to establish tight 
regulation of the expression of many genes.  For example, examination of histone modifying 
enzymes during mitosis, using quantitative in situ imaging techniques, revealed that histone 
acetyltransferases and histone deacetylases move from disassembled interchromosomal spaces 
back into distinct foci as cells enter early G1 phase, concomitant with the reactivation of their 
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respective activities (Kruhlak et al., 2001). 
Chromatin structure also plays a role in regulating cell cycle arrest and differentiation.  
Current literature supports the view that differentiation-specific transcription factors can inhibit 
transcription of cell cycle genes by targeting histone deacetylases to promoter sites, permitting 
transcriptional repression by the histone-modifying enzyme (reviewed in Cheung et al., 2000).  
For example, C/EBP! associates with p300/CBP, which has histone deacetlyase activity, and 
with the Brm subunit of SWI/SNF chromatin remodeling complex in order to regulate specific 
genes during growth arrest and differentiation (Erickson et al., 2001; Pedersen et al., 2001).  
Secondly, transcription factors may recruit histone acetyltransferase complexes in order to 
silence the expression of other genes in order to regulate cellular fate (Cheung et al., 2000). 
 Several types of nuclear bodies have been implicated as sites of transcriptional activity, 
while others provide a stable but transcriptionally inactive site for protein complex assembly or 
for storage.  Moreover, some transcription factors may associate with different subnuclear 
domains depending on the state of the cell.  For example, Parfenov and colleagues (2003) used 
a variety of imaging tools to demonstrate that the transcription factor Oct-4 is found at dense 
fibrillar components of the nucleolus and is associated with RNAPII at perichromatin fibrils 
and interchromatin granules during the transcriptionally active stage of the mouse oocyte 
nucleus.  However, in transcriptionally inert oocytes, Oct-4 becomes localized to perichromatin 
granules, nucleolus-like bodies and Cajal bodies (Parfenov et al., 2003).  Alternatively, 
regulation of nuclear factor may occur in response to cellular signals in response to a stimulus 
(reviewed in Corry and Underhill, 2005).  It has been demonstrated that heat shock factors are 
activated in response to cellular stress by inducing the expression of proteins involved in the 
maintenance of intracellular homeostasis.  In these conditions, transient subnuclear domains are 
formed, termed nuclear stress granules, where proteins responsible for cellular maintenance 
accumulate and may form protein complexes and/or work together to activate transcription of 
specific genes. 
 
2.3.3  Subnuclear Characterization of C/EBP! and TCERG1 
 
Several studies have examined the subnuclear compartmentalization of C/EBP! in a 
variety of cells lines (Tang and Lane, 1999; Schaufele et al., 2001, 2003; Zhang et al., 2001; 
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Liu et al., 2002, 2007; Day et al., 2003; Enwright et al., 2003; Demarco et al., 2006).  The 
pattern of subnuclear distribution of C/EBP! in murine-derived cell types is defined by the 
presence of 20-50 distinct punctate foci localized near centromeres of interphase 
heterochromatin (Tang and Lane, 1999; Schaufele et al., 2001).  In studies looking at the 
subnuclear localization of C/EBPs during adipocyte differentiation, it was found that when 
C/EBP" is first expressed, it is localized throughout the nucleoplasm (Tang and Lane, 1999).  
Within 12 to 16 hours of expression, C/EBP" acquired DNA-binding activity and was 
subsequently localized to peri-centromeric regions, while C/EBP$ remained dispersed 
throughout the non-nucleolar regions of the nucleoplasm (Tang and Lane, 1999).  Moreover, 
the ability to redistribute to peri-centromeric regions was thought to be dependent on 
phosphorylation of C/EBP", which was later confirmed by immunofluorescence using 
phospho-specific antibodies directed to sites targeted by mitogen-activated protein kinase in 
cells treated with growth hormone (Tang and Lane, 1999; Piwien Pilipuk et al., 2003).  Cell 
fractionation and in situ immunofluorescence studies demonstrated that there was a delay 
between C/EBP" expression, sequestration to peri-centromeric regions and DNA binding to the 
promoter region of c/ebp! (Tang and Lane, 1999).  The DNA binding capacity is also thought 
to be as a result of the phosphorylation C/EBP" that occurs shortly after the induction of its 
expression.  Observations reported for C/EBP! were identical to C/EBP", suggesting that both 
isoforms undergo similar mechanisms involved in peri-centromeric relocalization in a DNA 
binding-dependent manner (Tang and Lane, 1999).  This was one of the initial reports 
describing and relating the subnuclear localization of C/EBPs, post-translational modification 
and DNA binding activity (Tang and Lane, 1999).  Since then, evidence suggests that mouse 
major !-satellite DNA repeat sequences found within transcriptionally inert peri-centromeric 
regions are responsible for the sequestration of C/EBP! to these domains (Liu et al., 2007).  
Furthermore, examination a C/EBP! molecule containing only the bZIP domain was sufficient 
to target the molecule to peri-centromeric heterochromatin, yet a mutant whose leucine zipper 
was removed could no longer associate with these subnuclear structures (Schaufele et al., 2001; 
Liu et al., 2002).  Interestingly, an amino acid substitution of valine to alanine at position 296 
resulted in the abrogation of DNA binding to !-satellite sequences found at peri-centromeric 
regions and was instead distributed in the interchromatin space generally associated with 
transcriptional activity (Schaufele et al., 2001; Liu et al., 2007).  This inability to localize to 
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peri-centromeric regions also led to increased levels of C/EBP!-mediated transcriptional 
activity of certain promoters localized in interchromatin space (Liu et al., 2007).  Thus, the 
DNA-binding domain of C/EBP! is both sufficient and necessary for proper targeting to peri-
centromeric heterochromatin in GHFT1-5 and 3T3-l1 cell lines (Schaufele et al., 2001; Liu et 
al., 2002, 2007).  Additional studies by Liu et al. (2007) demonstrated that pituitary-specific 
positive transcription factor-1 (Pit-1) sequestered C/EBP! away from peri-centromeric domains 
to sites occupied by Pit-1 in a dispersed nucleoplasmic pattern containing euchromatin.  Thus, 
peri-centromeric subnuclear compartments have been attributed to act as stable storage sites 
where C/EBP! is concentrated and can be released or recruited to areas of active transcription.  
Additional support for this hypothesis came from reports by Day et al. (2003) and Enwright et 
al. (2003) who demonstrated that DNA binding by C/EBP! at !-satellite DNA is a prerequisite 
to its recruitment by Pit-1 and their subsequent cooperative transcriptional activity at pituitary-
specific promoters.  This evidence suggests that C/EBP! is maintained and stored in peri-
centromeric regions prior to recruitment and cooperative activation of specific promoters by 
Pit-1.  Moreover, a truncation mutant of C/EBP! missing the TAD is able to interact with Pit-1 
but both C/EBP! and Pit-1 remain associated with peri-centromeric regions.  Further 
characterization of the interactions between Pit-1 and C/EBP! using fluorescence resonance 
energy transfer analysis to visualize living GHFT1-5 pituitary cells suggest that protein 
domains that specify re-localization are separate from those involved in the direct functional 
and stable positioning within the subnuclear architecture.  This hypothesis recapitulates the data 
demonstrating that DNA binding activity and localization to inactive heterochromatin by 
C/EBP! is required for interactions with Pit-1 and for the ensuing redistribution of Pit-
1/C/EBP! complexes to euchromatic regions containing active transcription.  Similar 
requirements for DNA-binding and phosphorylation have been described for proper peri-
centromeric heterochromatin localization of Ikaros, a transcription factor expressed in 
hematopoietic cells that regulates the expression of lymphocyte-specific genes (Brown et al., 
1997; Cobb et al., 2000; Gurel et al., 2008).  The DNA-binding and dimerization domains of 
Ikaros were essential for proper localization in several different cell lines, suggesting that the 
requirements for subnuclear compartmentalization is an intrinsic property of Ikaros, and that the 
pattern of distribution is not limited to lymphocyte cells (Cobb et al., 2000).  Subsequent 
characterization of Ikaros subnuclear localization revealed that phosphorylation was important 
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for the ability of Ikaros to acquire peri-centromeric occupancy and that reversible 
phosphorylation of specific residues controls subnuclear localization and regulation of Ikaros 
transcriptional activity during the differentiation of thymocytes (Gurel et al., 2008).  Data 
collected from studies examining the relationship between peri-centromeric localization of 
Ikaros and the regulation of its function appear to be analogous to observations made with 
C/EBP! and, thus, have provided insight for a functional role for subnuclear localization in the 
control of C/EBP! activity. 
Recent studies have demonstrated that certain nuclear co-factors can be recruited to 
peri-centromeric regions in a C/EBP!-dependent manner (Schaufele et al., 2001, 2003).  This 
suggests that these sites may also act as assembly stations for the formation of protein 
complexes that can then be recruited to various regions of active transcription.  CBP and TBP, 
two enhancers of C/EBP! transcriptional activity, are generally localized in a reticular pattern 
throughout the nucleus of GHFT1-5 cells (Schaufele et al., 2001).  However, when each is co-
expressed with C/EBP!, CBP and TBP rapidly become associated with peri-centromeric 
regions.  Moreover, redistributon of CBP and TBP requires binding through the TAD of 
C/EBP!, which reaffirms the concept that protein domains specifying co-localization are 
distinct from those that direct functional positioning of protein complexes within the nuclear 
substructure, as proposed by Day and colleagues (2003).  Finally, it has been demonstrated that 
C/EBP! regulates the levels of acetylated histone H3 present at peri-centromeric regions 
(Zhang et al., 2001).  Increased levels of histone H3 acetylation are dependent on the 
transcriptional integrity of C/EBP! (Zhang et al., 2001).  This was demonstrated using two 
C/EBP! mutants: one whose TAD was deleted, and the other inactivated (Schaufele et al., 
2001) by forming a fusion protein with the carboxy-terminal domain of EGFP (Zhang et al., 
2001).  The amount of acetylated H3 remained at levels similar to cells not expressing C/EBP! 
to when each C/EBP!  mutant was expressed (Zhang et al., 2001).  It is known that C/EBP! 
interacts with and recruits co-regulators that modify chromatin structure and histone 
acetylation, such as CBP and p300 (Erickson et al., 2001), which can alter the accessibility of 
genes to regulatory proteins involved in mediation of transcriptional activation or repression.  
Thus, control over the expression of certain genes found in proximity to peri-centromeric 
regions may be subject to C/EBP!-dependent regulation and may be important during cellular 
growth arrest or terminal differentiation.  Collectively, whether acting as a stable storage 
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facility, as a site for protein complex assembly, or in the regulation of chromatin structure, 
subnuclear compartmentalization of C/EBP! appears to be an important component in the 
regulation and function of C/EBP!-mediated activities. 
Recent studies have examined the dynamics of other nuclear bodies, such as the splicing 
factor-rich nuclear speckles.  Data suggests that nuclear speckles serve as storage sites for 
nuclear factors involved in transcription and pre-mRNA splicing, such as RNApII and SC35, 
respectively (Bregman et al., 1995; Mortillaro et al., 1996; Miteli et al., 1997; Melcak et al., 
2000; Mintz and Spector, 2000; Hall et al., 2006).  Moreover, pinin/DRS, a cell adhesion-
related protein and mRNA processing factor that primarily localizes within nuclear speckles, 
was recently found to drastically redistribute to the nucleoplasm and cytosol upon the 
overexpression of the transcription factor C-terminal binding protein 1 (Alpatov et al., 2004).  
Additionally, pinin/DRS was shown to relieve C-terminal binding protein 1-mediated 
transcriptional repression at certain promoters by a functional interaction between the two 
proteins.  These studies and others provide mounting evidence for the functional association 
between nuclear proteins involved in mRNA processing, transcriptional activity and alterations 
in nuclear localization (Carty et al., 2000; Goldstrohm et al., 2001; Alpatov et al., 2004).  
Therefore, since TCERG1 is thought to act as a bridge between transcription and splicing, 
subnuclear localization may play a role in TCERG1-mediated inhibition of C/EBP! activity. 
As the characterization of TCERG1 continues to be pursued, a singular study has 
examined the specific subnuclear distribution of this elusive nuclear factor (Sanchez-Alvarez et 
al., 2006).  Using indirect immunostaining techniques, the spatial distribution of endogenous 
TCERG1 in HeLa and non-transformed IMR90 fibroblast cell lines has been recently described 
by Sanchez-Alvarez et al. (Sanchez-Alvarez et al., 2006).  In this study, several experiments 
were performed to establish that TCERG1 accumulates within two non-nucleolar populations: 
mainly in splicing factor-rich nuclear speckles and at lower levels heterogeneously dispersed 
throughout the nucleoplsm.  Subsequent deletion analysis of TCERG1 suggested that the FF 
domains found within in the carboxy-terminal domain are important for proper nuclear speckle 
localization.  This finding is supported by the fact that TCERG1 associates with the 
hyperphosphorylated carboxy-terminal repeat of RNAPII, which is also a component of nuclear 
speckles (Bregman et al., 1995; Mortillaro et al., 1996; Carty et al., 2000).  Finally, Arango et 
al. (2006) were able to show that the (QA)38 repeat was important for TCERG1 nuclear 
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localization in the nuclei of primary rat striatal cells using immunofluorescence and LSCM, 
although this requirement has not been examined in other cell lines.  Therefore, it is possible 
that function(s) provided by different domains are important for nuclear localization of 
TCERG1 in a tissue-dependent manner. 
 
2.3.4  Nuclear Localization is Important for Transcription Factor Activity 
 
Given that TCERG1 and C/EBP! localize within different and distinct subnuclear 
compartments, LSCM can be used to examine any alterations in subnuclear localization that 
may occur upon their co-expression.  It is unknown if subnuclear localization is involved in the 
TCERG1-mediated inhibition of C/EBP! activity, however, if such a mechanism exists, several 
scenarios can be predicted.  First, C/EBP! activity may be inhibited by a mechanism mediated 
by TCERG1, either by direct or indirect association, resulting in restricted mobility or 
accessibility of C/EBP! to various subnuclear domains where it functions.  Additionally, 
interactions between C/EBP! and TCERG1 may prevent association with co-activators, such as 
CBP and TBP, by limiting the number of free C/EBP! molecules able to form active protein 
complexes.  Both mechanisms would result in the confinement and accumulation of C/EBP! 
within inactive nuclear domains, thereby detaining C/EBP!, and preventing access to all sites 
of activity altogether.  Moreover, the concept of a nuclear retention mechanism has been 
described for several nuclear factors found within the nucleolus and with RNAPII in response 
to alterations in physiological cellular conditions or by chemical inhibitors, respectively 
(Misteli et al., 1997; Gorski et al., 2006).  Although the aforementioned hypothetical models 
are with respect to inhibition of C/EBP! activity, a similar mechanism involving protein 
mobility and subnuclear structure has been described for the co-operative transcriptional 
activation of C/EBP! and Pit-1 in GHFT1-5 pituitary cells (Demarco et al., 2006).  In this 
model, the assembly of the protein complex, Pit-1/C/EBP!, is stabilized by the dominant 
chromatin-binding activities of Pit-1, leading to decreased C/EBP! mobility.  This permits 
stable association of the protein complex with a particular nuclear subdomain, such as 
transcriptionally active euchromatin.  This hypothesis was further emphasized by the analysis 
of a single missense mutation in Pit-1 that abrogated the dominant chromatin-binding activity, 
resulting in the formation of protein complexes with C/EBP! restricted to peri-centromeric 
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regions.  A third mechanism of inhibition may involve the recruitment of C/EBP! to an entirely 
different nuclear body where there is no C/EBP! activity.  As a result, access to factors 
involved in recruiting or activating C/EBP! transcriptional activity would be prohibited.  This 
mechanism of inhibition has been observed with C/EBP$, which is involved in differentiation 
and growth arrest of mouse mammary epithelial cells (O'Rourke et al., 1999; Zhou et al., 2008).  
In co-localization studies examined by LSCM, Zhou et al. (2008) were able to demonstrate that 
a potent inhibitor of C/EBP$ activity, protein inhibitor of STAT-y (PIASy), repressed the 
activities of C/EBP$ in part by sequestering it to the nuclear periphery of HC11 mouse 
mammary epithelial cells.  PIASy also inhibits the activities of transcription factors by 
sumoylation, reducing DNA binding, and recruiting histone deacetylases (Kim et al., 2002; 
Schmidt and Muller, 2003; Zhou et al., 2008).  However, re-localization of C/EBP$ by direct 
interaction with PIASy occurs independent of other forms of inhibition, suggesting 
translocation of C/EBP$ alone may be sufficient to inhibit its activity (Zhou et al., 2008).  
Furthermore, it was suggested that inhibition of C/EBP$ activity could also be a consequence of 
interaction or association with additional transcription factors found at the nuclear periphery, a 
region considered to be transcriptionally inert (Shaklai et al., 2007; Zhou et al., 2008).  Finally, 
“scratch” assays were performed to examine the effect of PIASy expression on the biological 
role of C/EBP$-mediated control of cellular proliferation and migration (Zhou et al., 2008).  
These in vitro assays are designed such that a small area of confluent monolayer of HC11 
cultured cells was removed using a pipette tip (scratch), thereby inducing the proliferation and 
migration of cells into the open area.  Cells transiently transfected with C/EBP$ and PIASy 
demonstrated enhanced ability to repopulate “scratch” regions, versus cells expressing only 
C/EBP$.  Collectively, these studies suggest that PIASy inhibits the transcriptional and growth 
arrest activity of C/EBP$ in HC11 mammary epithelial cells by sequestering C/EBP$ to the 
transcriptionally inactive nuclear periphery.  Thus, it is possible that other C/EBP isoforms can 
be negatively regulated by a similar mechanism, such as the inhibition of C/EBP! by TCERG1. 
Splicing factor-rich nuclear speckles are thought to be storage sites for various splicing 
factors in addition to other factors required for transcription, such as hyperphosphorylated 
RNAPII (Bregman et al., 1995).  Studies by Misteli et al. (1997) demonstrated that components 
of nuclear speckles have the ability to translocate to various sites of active transcription.  
Futhermore, it has been demonstrated that splicing factor SC35 can diffuse out of nuclear 
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speckles into transcriptionally active regions at peri-chromatin fibrils and can participate in pre-
mRNA splicing (Melcák et al., 2000).  Based on these observations, it is possible that TCERG1 
may translocate to areas surrounding or occupied by C/EBP! where it can bind to and inhibit 
C/EBP! activity responsible for arresting cellular proliferation and/or transcriptional activation.  
Additional evidence to support the hypothesis for the re-distribution of TCERG1 by C/EBP! is 
based on a recent study showing the ability of C/EBP! to recruit subnuclear factors, CBP and 
TBP, to peri-centromeric regions in mouse progenitor pituitary GHTF1-5 cells (Schaufele et al., 
2001).  This demonstrates that C/EBP! has the ability to recruit transcriptional co-factors to 
subnuclear compartments occupied by C/EBP!.  Moreover, this function may not be limited to 
co-activators and may include the recruitment of negatively acting factors like TCERG1 as 
well. 
 
 
2.4  Hypothesis 
TCERG1 inhibits the growth arrest activities of C/EBP! through functional motif(s) that 
lie exclusively in the amino-terminal region of TCERG1 and the mechanism by which this 
occurs involves subnuclear localization. 
 
 
2.5  Objectives and Rationale 
 
A.  To identify the region(s) of TCERG1 responsible for inhibiting C/EBP!-mediated 
growth arrest in cultured cells using growth arrest assays. 
Recently data demontrated that TCERG1 inhibits C/EBP!-mediated growth arrest 
activity in several cell lines (McFie et al., 2006).  Additional evidence suggests that TCERG1 
interacts with C/EBP! through domains found within the amino-terminal domain.  Thus, 
mutants of TCERG1 were generated and tested in growth arrest assays with cells expressing 
C/EBP! in an effort to map the regions responsible for mediating TCERG1 inhibitory activity.  
A transfection-based proliferation assay in combination with fluorescence technology allows 
the observation and quantification of cells expressing fluorescent fusion proteins to TCERG1 
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and C/EBP!.  Each TCERG1 mutant was examined for its ability to reverse growth arrest of 
cultured cells co-expressing C/EBP!-EGFP. 
 
B.  To determine the nuclear distribution of both C/EBP!-EGFP and mCherry-TCERG1 
using LSCM when co-expressed in cultured cells as a possible mechanism for inhibition of 
C/EBP! by TCERG1. 
Evidence from a variety of studies suggests that components of several nuclear bodies 
have the ability to translocate to areas of active transcription and/or sites where splicing events 
occur (Misteli et al., 1997, 2008b; Melcak et al., 2000; Phair and Misteli, 2000; Carmo-
Fonseca, 2002; Faro-Trindade and Cook, 2006; Gorski et al., 2006).  Additionally, it has been 
shown that some nuclear factors can be recruited to other nuclear structures as a means of 
inhibition (Finlan et al., 2008; Zhou et al., 2008).  Moreover, it has been demonstrated that 
C/EBP! can recruit co-activators to peri-centromeric regions in GHFT1-5 progenitor pituitary 
cells where transcriptionally active protein complexes may be formed (Schaufele et al., 2001).  
Therefore, using LSCM (Matera, 1999; Misteli, 2001; Wang et al., 2002b; Iborra et al., 2003), 
the relationship of the inhibitory function of TCERG1 and spatial distribution between 
TCERG1 and C/EBP! was characterized.  Different fluorescent protein fusions to TCERG1 
and C/EBP! were co-expressed in two cell lines and examined for any alterations in their 
subnuclear localization patterns relative to conditions where each were expressed alone. 
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3.  MATERIALS AND METHODS 
 
 
3.1  Reagents 
 
 All reagents used were of analytical grade or higher.  Names of reagents and suppliers 
are listed in Table 1.  Addresses for each supplier are subsequently listed in Table 2. 
 
Table 1:  List of Reagents and Suppliers. 
 
Reagent Supplier 
Common Reagents   
100 base pair (N3231), 1 kilobase pair 
(N3232) DNA ladder 
NEB 
Calf Intestinal Alkaline Phosphatase (M0290) NEB 
DNA-Modifying Enzymes NEB 
Paraformaldehyde BDH 
Polyethylenimine Polysciences 
T4 DNA Ligase (15224) Invitrogen 
T4 Polynucleotide Kinase (M0201) NEB 
  
Bacterial Culture Reagents   
Ampicillin Unison Biotek 
Kanamycin ICN 
NM522 Competent Escherichia coli  Stratagene 
NZ-Amine A
®
 from Bovine Milk Sigma-Aldrich 
XL-10 Gold
®
 Ultracompetent Escherichia 
coli  
Stratagene 
  
Commerical Kits   
QIAquick
®
 Gel Extraction Kit Qiagen 
QIAquick
®
 PCR Purification Kit Qiagen 
  
Cell Culture Reagents   
Antibiotic-Antimycotic (100x) Invitrogen 
Dulbecco's Modified Eagle's Medium  - Low 
Glucose (D6046) 
Sigma-Aldrich 
Fetal Bovine Serum (Canadian Origin) PAA  
Trypsin, 0.25 % (1x), EDTA•4 Na Invitrogen 
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Reagents for Immunofluorescence  
ColorpHast
®
 pH Test Stripe Non-Bleeding pH 
0-14 
EMD 
pmCherry-C1 Mammalian Expression Vector Clontech 
Prolong
®
 Gold Antifade Reagent with 4’,6-
diamidino-2-phenylindole 
Invitrogen 
Vista Vision Cover Glasses No. 1.5 VWR 
  
Protein Analysis Reagents   
30% Acrylamide/Bis Solution (29:1) Bio-Rad 
Autoradiography Film Denville Scientific 
PageRuler
TM
 Prestained Protein Ladder Plus 
(SM1811) 
Fermentas 
Western Lightning
TM
 Chemiluminescence 
Reagent Plus Kit 
Perkin Elmer 
 
 
 
Table 2:  List of Names and Addresses of Reagent Suppliers. 
 
Supplier Address 
Abcam Cambridge, Massachusetts, USA 
BDH Saskatoon, Saskatchewan, Canada 
Bethyl Labs Montgomery, Texas, USA 
Bio-Rad Hercules, California, USA 
Clontech Mountain View, California, USA 
Denville Scientific Metuchen, New Jersey, USA 
EMD Madison, Wisconsin, USA 
Fermentas Burlington, Ontario, Canada 
ICN St. Laurent, Quebec, Canada 
Invitrogen Burlington, Ontario, Canada 
NEB Mississauga, Ontario, Canada 
PAA  Etobicoke, Ontario, Canada 
Perkin Elmer Boston, Massachusetts, USA 
Polysciences Warrington, Pennsylvania, USA 
Qiagen Mississauga, Ontario, Canada 
Santa Cruz Santa Cruz, California, USA 
Sigma-Aldrich Oakville, Ontario, Canada 
Stratagene La Jolla, California, USA 
Unison Biotek Scarborough, Ontario, Canada 
VWR  Mississauga, Ontario, Canada 
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3.2  Bacterial Strains and Media Preparations 
 
E. coli NM522 and XL10-Gold® ultracompetent E. coli cells (Stratagene, California, 
USA) were used as the host for the amplification of plasmid DNA. 
Luria-Bertani (LB) agar plates containing either kanamycin or ampicillin were used to 
propagate both E. coli strains.  In general, LB plates were prepared by combining 10 g bacto-
tryptone, 5 g bacto-yeast extract, 10 g NaCl and 15 g bacto-agar in 1 L double distilled water 
(ddH2O) and subsequently sterilized by autoclaving for 20 min at 15 lb/sq. in.  Once cooled to 
45-50°C, kanamycin was added with a final concentration of 50 'g/mL or ampicillin to 100 
'g/mL, then poured into 100 mm Petri dishes and stored at 4˚C until used. 
LB liquid medium used to prepare competent E. coli NM522 cells was prepared as 
indicated above with the exception that no agar or antibiotics were added.  Appropriate 
antibiotics were added when required for the propagation of bacterial cells. 
NZY broth used in the transformation protocol of XL10-Gold
® 
ultracompetent E. coli 
cells (Stratagene) was made from 10 g NZ-Amine A
®
 casein hydrolysate from bovine milk, 5 g 
yeast extract, and 5 g NaCl in 1 L ddH2O.  The mixture was adjusted to pH 7.5 and then 
autoclaved.  Prior to use, NZY broth was supplemented with the addition of sterile 0.004% 
(w/v) glucose, 12.5 mM MgCl2 and 12.5 mM MgSO4. 
For small and large quantity plasmid DNA isolation, a single E. coli colony was 
inoculated in complete Terrific Broth (TB) medium.  TB was prepared by combining 12 g of 
bacto-tryptone, 24 g of bacto-yeast extract and 4 mL glycerol in 900 mL ddH20 and then 
autoclaved.  Once cooled, 100 mL potassium-salt solution (0.17 M KH2PO4 and 0.72 M 
K2HPO4) and the appropriate antibiotics were added. 
 
 
3.3  Molecular Cloning 
 
 Protocols in this section were based in part on those described in Sambrook et al. 
(1989). 
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3.3.1  Preparation of Competent Bacterial Cells 
 
 Two mL of LB were inoculated with a single colony of E. coli and incubated overnight 
at 37˚C with agitation.  The culture was transferred to a flask containing 200 mL LB and 
incubated at 37˚C with agitation for 1-2 h until O.D.590 reached 0.375.  The bacterial culture 
was transferred into pre-chilled 50 mL sterile conical tubes and incubated on ice for 10 min.  
Following incubation, cultures were centrifuged at 7000 X g for 10 min to pellet the cells.  The 
supernatant was decanted and cells resuspended in 10 mL cold CaCl2 wash solution (60 mM 
CaCl2, 15% glycerol, 10 mM 2-[4-(2-sulfoethyl)piperazin-1-yl]ethanesulfonic acid, pH 7.0).  
Samples were again subjected to centrifugation and resuspended in 10 mL CaCl2 wash solution 
and then placed on ice for 30 min.  Cells were then centrifuged at 7000 X g, the supernatant 
removed, and the pellet resuspended in 2 mL CaCl2 solution.  The competent bacteria were 
aliquoted into sterile 1.5 mL cryovials and stored at -80˚C. 
 
3.3.2  Transformation of Competent Bacterial Cells 
 
E. coli NM522 cell stocks were thawed on ice.  In a pre-chilled 14 mL polypropylene 
tube, 100 'L E. coli cells plus 2 'L DNA ligation reaction were gently mixed and placed on ice 
for 30 min.  Following incubation, the transformation mixture was heat-pulsed at 42˚C for 2 
min and then returned to ice for 2 min.  The transformation mixture was spread onto LB plates 
containing the appropriate antibiotic, inverted and incubated overnight at 37˚C.  
 Transformation of XL10-Gold
®
 ultracompetent E. coli cells was performed as described 
in the protocol provided by the manufacturer. 
 
3.3.3  Small Scale Plasmid DNA Preparations 
 
 The protocol used to isolate small scale plasmid DNA was adopted from a protocol by 
Lee and Rasheed (1990).  Single E. coli colonies were selected and individually inoculated into 
5 mL complete TB containing the appropriate antibiotic.  For amplification of plasmids with 
kanamycin resistance, cultures were grown in complete TB for 1 h with agitation at 37˚C before 
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kanamycin was added.  In the final step, all plasmids were resuspended in 10 mM Tris-HCl and 
1 mM EDTA, pH 8.0. 
 
3.3.4  Large Scale Plasmid DNA Preparations 
 
 Plasmid DNA was extracted from lysed E. coli cells as described by Sambrook et al. 
(1989).  A single E.coli colony was inoculated in 5 mL TB and incubated at 37˚C with agitation 
for 6-18 hr.  The bacterial culture was then added to 200 mL complete TB containing the 
appropriate antibiotic and incubated with agitation overnight at 37˚C.  The final pellet 
containing plasmid DNA was resuspended in 10 mM Tris-HCl and 1 mM EDTA, pH 8.0, to a 
final concentration of 1.0 'g/'L.  Plasmids were deemed to be of sufficient purity when the 
O.D.260/280 ratio was between 1.7 and 1.8. 
 
3.3.5  Plasmids 
 
 A series of TCERG1 mutants each consisting of the following amino acids: 32-1098, 
32-668, 32-293, 281-1098, and 641-1098 were constructed previously in our laboratory (Pam 
McFie) by ligating the coding region of each into the BglII/EcoRI site of pHA3.  pHA3 contains 
three tandem hemagglutinin (HA3) epitopes cloned into pRc-CMV (Invitrogen) 5’ to the insert 
of interest so that the resulting protein contains three HA epitopes fused to the amino-terminal 
region.  pHA3 was kindly provided by D. Anderson (Saskatoon Cancer Centre).  Additionally, a 
simian virus 40 (SV40) large T-antigen NLS (Ohno and Shimura, 1996) was cloned in frame 
into the BglII restriction site at the amino terminus of TCERG1 truncation mutants 641-1098 
and 32-293 to facilitate nuclear localization of these mutants whose endogenous NLS was 
deleted.  The generation of pHA3 641-1098 and pHA3 32-293 is described in more detail in 
section 3.3.5.3. 
The following describes the generation of pmCherry-TCERG1 mutants used in this 
study.  pmCherry-C1 mammalian expression vector encodes a monomeric red fluorescent 
protein derived from Discosoma striata (DsRed) and has been modified to reduce cellular 
toxicity in addition to increased stability relative to other variants of  DsRed (Shaner et al., 
2004).  The excitation and emission maxima for mCherry are 587 nm and 610 nm, respectively.  
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Vectors containing mCherry-TCERG1 mutants were constructed by isolating the BglII/HindIII 
(32-668, 32-293) or BglII/EcoRI (32-1098, 281-1098, 641-1098) fragment from pHA3-
TCERG1 mutants then ligated in-frame into pmCherry.  Both pmCherry-TCERG1 32-668 and 
32-293 retained the HA3 tag as well as the SV40 NLS in 32-293 (see section 3.3.5.3 for 
generating pHA3-TCERG1 32-293).  Each TCERG1 mutant generated was subjected to 
diagnostic restriction analysis and then sent to PBI-NRC (Saskatoon, Saskatchewan, Canada) 
for DNA sequence verification. 
For both growth arrest and co-localization studies, a vector encoding enhanced green 
fluorescent protein (EGFP) was used to assist in visualization.  pEGFP-N1 (Clontech) contains 
a multiple cloning site for a cDNA insert of interest in-frame with the amino-terminal end of 
EGFP (Yang et al., 1996).  EGFP is a red-shifted derivative of wild-type GFP from Aequorea 
victoria with two distinguishing alterations.  A double amino acid substitution of Phe to Leu at 
position 64 and Ser to Thr at position 65 results in a significant increase in the fluorescence 
intensity relative to wild-type GFP (Cormack et al., 1996).  Additionally, higher levels of 
expression of EGFP in mammalian systems were achieved by human codon optimization.  The 
excitation and emission maxima for EGFP are 488 nm and 507 nm, respectively.  pEGFP-N1 
and pEGFP-N1-C/EBP! were a gift from R. Day (Indiana University School of Medicine).  
pEGFP-N1-C/EBP!  has been renamed as pC/EBP!-EGFP since EGFP is fused to the carboxy-
terminal end of C/EBP! . pC/EBP!-EGFP also contains a FLAG epitope fused to the amino-
terminus of C/EBP!-EGFP for detection purposes if necessary. 
Additional vectors used in co-localization studies are described as follows: pEGFP-LAP 
encodes EGFP fused to the amino-terminal region of liver activating protein (LAP) isoform of 
C/EBP! and was a gift from C. Asselin (Université de Sherbrooke).  pEGFP-Sp1, a gift from 
O. Rohr (Université de Strasbourg), was generated by cloning the Sp1 cDNA into the 
XhoI/HindIII sites of pEGFP-C1 (Clontech). 
 
3.3.5.1  Restriction Digest of Plasmid DNA 
 
All DNA-modifying enzymes were purchased from New England Biolabs (NEB) unless 
otherwise stated.  In a total volume of 20 'L, 2 'g plasmid DNA, 10 U of each restriction 
enzyme, and 2 'L appropriate 10X buffer were added, mixed and incubated at 37°C for 1-2 h. 
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3.3.5.2  DNA Fragment Isolation and Verification 
 
 In order to verify and isolate plasmid DNA fragments, DNA was subjected to agarose 
gel electrophoresis after digestion with restriction enzymes.  DNA samples were resuspended in 
2 'L of 6X sample loading buffer (25 mM bromophenol blue, 25 mM xylene cyanol FF, 30% 
glycerol) before loading into a 1% agarose gel containing 1X TAE (40 mM Tris-Acetate, 1 mM 
EDTA, pH 8.0) and 1 'g/mL ethidium bromide.  A 1 kilobase pair or 100 base pair DNA 
ladder was also loaded as appropriate.  Electrophoresis was carried out in an apparatus 
containing 1X TAE buffer for 1 h at 100 volts.  When required, the DNA fragment of 
appropriate size was excised and purified using a QIAquick
®
 Gel Extraction Kit as described by 
the manufacturer. 
 
3.3.5.3  Generation of Nuclear Localization Signal TCERG1 Mutants 
 
 The following protocols describe the generation of TCERG1 32-293 and 641-1098 
truncation mutants in the pHA3 expression plasmid. 
 
3.3.5.3.1  Dephosphorylation of Plasmid DNA 
 
 Previously digested plasmid DNA was purified using a QIAquick
®
 Gel Extraction Kit.  
In a 500 'L microcentrifuge tube, 5 'g of plasmid DNA was resuspended in a solution 
containing 1X NEB buffer 3, 10 U calf intestinal alkaline phosphatase in a total volume of 20 
'L and incubated in a 37°C water bath for 1 h.  The resulting plasmid DNA was purified using 
a QIAquick
®
 PCR Purification Kit as described by the manufacturer. 
 
3.3.5.3.2  Preparation of the SV40-NLS Oligonucleotide Fragment 
 
 The SV40 large-T antigen NLS (Ohno and Shimura, 1996) was generated from 
complementary oligonucleotides:  forward 5'-GATCCCCTAAGAAGAAGAGGAAAGTCA-3' 
and reverse 5'-GATCTGACTTTCCTCTTCTTCTTAGGG-3' (Invitrogen) which code for 
amino acids PKKKRKV.  Proper orientation of the NLS was established by the ligation of five 
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nucleotides (underlined) of the forward oligonucleotide with the 3’ BglII site of the vector.  
This was achieved by the introduction of a single nucleotide point mutation in the BglII site, 
effectively removing it.  The SV40-NLS oligonucleotides were first annealed by placing 10 µg 
of each primer diluted with 0.1X TE in a final volume of 100 'L, incubated in a water bath at 
95°C for 5 min then slowly cooled to room temperature (RT).  Next, 400 ng of annealed 
oligonucleotide was then phosphorylated with 10 U T4 polynucleotide kinase, 1X T4 
polynucleotide kinase buffer and 10 mM ATP in a final volume of 10 'L.  The sample was 
incubated at 37°C for 30 min, followed by 5 min at 70°C to inactivate T4 polynucleotide 
kinase. 
 
3.3.5.3.3 Ligation of TCERG1 NLS Mutants into pHA3 and pmCherry-C1 
 
 Approximately 10-30 fmol of vector and 30-90 fmol double-stranded oligonucleotide 
were added to 10 U T4 ligase, and 4 'L 5X buffer, adjusted to 20 'L with ddH2O and 
incubated at RT overnight.  Two microlitres of the ligation reaction was transformed into either 
competent E. coli NM522 or XL10-Gold® ultracompetent E. coli as described above. 
 Expression vectors containing TCERG1 32-293 and 641-1098 were verified using 
restriction enzyme analysis and subjected to agarose gel electrophoresis performed on a 3% 
agarose gel with the same conditions as stated previously.  A 3% agarose gel was used to 
observe small differences in DNA fragment sizes corresponding to the SV40 NLS 27 base pair 
fragment.  Selected clones were sent to PBI-NRC (Saskatoon, Saskatchewan, Canada) for DNA 
sequence verification.  Each TCERG1 mutant contained one SV40 large T-antigen NLS with 
the exception of pmCherry-TCERG1 641-1098 which had two tandem repeats of the NLS. 
 
 
3.4  Mammalian Cell Culture 
 
 Human embryonic kidney 293T (HEK293T) cells, containing the gene for simian virus 
large T-antigen, were kindly provided by D. Muruve (University of Calgary).  African green 
monkey kidney cells (COS7) were provided by S. Stone (University of Saskatchewan).  All 
cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
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16.65 mM glucose and 5% fetal bovine serum at 37°C with 5% CO2.  Cells were passaged 
twice a week at 10-20% confluency and maintained in 100 mm tissue culture plates.  
Mammalian cell stocks were prepared by trypsinization and resuspended in 5 mL media, 
followed by centrifugation at 1500 X g for 5 min at 4°C.  The supernatant was removed, the 
cell pellet washed with 1X PBS, then resuspended in 1 mL of serum-containing DMEM with 
10% DMSO.  The cell suspension was then incubated for 1 h each at 4°C, -20°C, and -80°C 
before storing in liquid nitrogen. 
 
 
3.5  Growth Arrest Assay 
 
 COS7 cells were subcultured at 20% confluency into 60 mm tissue culture plates and 
transfected the following day.  In a 14 mL polypropylene tube containing 215 'L of 150 mM 
NaCl and 10 'g total DNA, 30 'L of 0.1% polyethylenimine was added and gently mixed 
immediately for 10 sec followed by a 10 min incubation at RT.  The transfection mixture was 
then added drop-wise to tissue culture plates containing cells and incubated at 37°C with 5% 
CO2.  Media was replaced 4 h post-transfection with fresh serum-containing media.  The 
following day, cells were resuspended first in a small volume of trypsin, and then in increasing 
volumes of serum-containing medium to ensure the majority of the cells were well separated.  
Cells were then seeded at 50% confluency into duplicate 60 mm tissue culture plates and 
incubated at 37°C with 5% CO2 for 24-48 h until visualized.  Between 140 and 160 individual 
green fluorescing cell colonies were assessed using an Olympus IX70 inverted fluorescent 
microscope (Olympus, Ontario, Canada).  Each fluorescing cell colony was categorized as 
either single cells exhibiting growth arrest or as clusters of two or more actively proliferating 
cells.  Images were captured using an imaging device coupled to the microscope and modified 
using SPOT advanced software (Diagnostic Instruments, Inc., Sterling Heights, Michigan, 
USA).  All data generated was obtained using a 9:1 plasmid ratio of pHA3-TCERG1 mutants to 
pC/EBP"-EGFP.  This ratio was achieved by expressing different plasmid ratios of pHA3-
TCERG1 32-1098 to pC/EBP!-EGFP from 2:1 to 9:1 in COS7 cells until reversal of growth 
arrest was demonstrated to levels similar to previous reports (McFie et al., 2006). 
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3.6  Protein Expression Determination by Western Blot Analysis 
 
 The following protocols are for the extraction and quantification of cellular protein and 
subsequent analysis using Western Blot procedure. 
 
3.6.1  Preparation of COS7 Cytosolic and Nuclear Extracts 
 
 The protocol described refers to cells propagated in 100 mm tissue culture plates.  
Transfected COS7 cells were washed once with cold 1X PBS before adding 1 mL cold low-salt 
buffer (20 mM HEPES, pH 7.5, 20% glycerol, 10 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 1 
mM dithiothreitol, and 0.1% Triton X-100).  Cells were harvested and homogenized using a 
Dounce homogenizer.  The cell lysates was transferred to a 14 mL polypropylene tube and 
pelleted by centrifugation at 7000 X g for 5 min.  The supernatant containing the cytosolic 
extract was removed to a fresh pre-chilled 14 mL tube and set aside.  The cell pellet was 
resuspended in 400 'L high-salt lysis buffer (20 mM HEPES, pH 7.5, 20% glycerol, 500 mM 
NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 1 mM DTT, and 0.1% Triton X-100) and was incubated 
on ice for 15-30 min followed by a 5-10 min incubation at RT.  The cell suspension was 
centrifuged at 1000 X g for 10 min at 4°C and the supernatant containing the nuclear extract 
was transferred to a fresh pre-chilled 1.5 mL ultracentrifuge tube.  All cellular extracts were 
quantified for protein concentration and prepared for SDS-PAGE electrophoresis as described 
in section 3.6.2 and 3.6.3. 
 
3.6.2  Protein Quantification of Cellular Extracts 
 
 For protein quantification, the Bio-Rad Protein Assay (Bio-Rad) was performed 
according to the microassay procedure supplied with the reagents.  Typically, one part 
concentrated dye reagent was diluted with four parts ddH2O.  In 1 mL of 1X dye reagent, 1 'L 
of cytosolic or nuclear extract was added, incubated at RT for 5 min then read at O.D.595 using a 
spectrophotometer.  A protein standard curve was performed using BSA ranging from 0-10 
'g/mL for determining sample protein concentration.   Samples were prepared for analysis by 
Western Blot by diluting them to 1 'g/'L in 5X SDS loading buffer (250 mM Tris, pH 6.8, 
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10% SDS, 50% glycerol, 1% bromophenol blue, and 25% !-mercaptoethanol), heating at 95°C 
for 5 min to denature proteins and placing them on ice before storing at -80°C.   
 
3.6.3  SDS Polyacrylamide Gel Electrophoresis 
 
 All protein samples were resolved on a 9% SDS polyacrylamide gel consisting of N,N’-
methylene-bis-acrylamide (29:1), 375 mM Tris-HCl, pH 8.8, 0.1% SDS, 0.1% ammonium 
persulfate, and 0.0004% N,N,N’,N’-tetramethylethanediamine, with a 4% stacking gel (N,N’-
methylene-bis-acrylamide (29:1), 130 mM Tris-HCl, pH 8.8, 0.1% SDS, 0.1% ammonium 
persulfate, and 0.001% N,N,N’,N’-tetramethylethanediamine).  A molecular weight marker,  
PageRuler
TM
 prestained protein ladder Plus, and approximately 15-20 'g denatured protein 
extracts were loaded onto the SDS-PAGE gel and subjected to electrophoresis at 125 volts for 
90 minutes using an Bio-Rad Mini Protean
®
 II Apparatus (Bio-Rad).  The running buffer was 
composed of 25 mM Tris-HCl, 192 mM glycine, and 0.1% (w/v) SDS. 
 The resolved samples were then transferred onto a polyvinylidene fluoride membrane 
using a Bio-Rad Mini Trans-Blot
®
 transfer cell filled with transfer buffer, pH 8.3 (48 mM Tris-
HCl, 39 mM glycine, 0.037% (w/v) SDS, and 20% methanol) and run at 75 volts for 3 hours or 
40 volts overnight at 4˚C.  The membrane was then removed and incubated in blocking buffer 
made with 5% blotting grade blocker non-fat milk/1X TBST, pH 7.5 (137 mM NaCl, 2.7 mM 
KCl, 19 mM Tris-HCl and 0.001% Tween-20) for 1 hour at RT with agitation.  The membrane 
was then incubated with the appropriate primary antibody diluted in 5% milk/1X TBST 
overnight at 4˚C to facilitate hybridization.  The following morning the membrane was washed 
three times with 5% milk/1X TBST for 10 minutes each and subsequently incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody diluted in 5% milk/1X 
TBST for 1 hour at RT with gentle agitation.  Following incubation, the membrane was washed 
once each with 5% milk/1X TBST, 1X TBST, and 1X Tris-buffered saline, pH 7.5 (137 mM 
NaCl, 2.7 mM KCl and 19 mM Tris-HCl) for 10 minutes before preparing for detection.  The 
membrane bound antibody-protein complexes were detected using Western Lightning 
Chemiluminescence Reagent Plus kit as described by the manufacturer and exposed on 
autoradiography film for an appropriate time at room temperature.  For a complete list of 
antibodies and the dilutions used, see Table 3. 
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3.7  Laser Scanning Confocal Microscopy  
 
3.7.1  Transient Transfection and Microscope Slide Preparation 
 
 HEK293T and COS7 cells were subcultured at 10-20 % and were transiently transfected 
using polyethylenimine as described in section 3.5 with the exception that cells were not 
resuspended in increasing volumes of serum-containing medium.  Cells were subsequently 
subcultured 1:2 12-24 h post-transfection in 6-well plates containing sterilized no. 1 1/2 glass 
cover slips.  Cells were maintained at 37°C with 5% CO2 for approximately 24 h before 
washing once with 1X PBS and fixed using a 4% (w/v) paraformaldehyde (PFA) solution (see 
next paragraph for preparation) for 15 min at RT.  Cells were washed three times with 1X PBS 
for 5 min.  Cover slips were air-dried and mounted onto microscope slides using Prolong#
 
Gold 
Antifade mounting media reagent plus 4’,6-diamidino-2-phenylindole and stored in the dark at 
RT for 24 h.  For experiments requiring immunofluorescence, cells were permeabilized using 
0.2-0.6 % Triton X-100 for 5-10 min at RT following fixation, and then washed twice with 1X 
PBS for 5 min.  Cells were blocked for 15 min at RT with 1 % (w/v) bovine serum albumin/1X 
PBS solution, followed by the addition of primary antibody diluted to 1:1000 using blocking 
solution and incubated at RT for 1 h.  Cover slips were then washed three times with 1X PBS 
for 5 min, then incubated with the appropriate Alexa Fluor# conjugated secondary antibody 
diluted to 1:200 using blocking solution for 45 min at RT.  Cover slips were washed five times 
with 1X PBS, air-dried and mounted as indicated above.  A complete list of antibodies and their 
applications used in this study are provided in Table 3. 
 The 4% (w/v) PFA fixation solution was prepared as follows.  Four grams of PFA were 
mixed with approximately 60 mL of 1X PBS, and then placed on a heating block while stirring 
until the solution reached 60˚C.  The heat source was turned off and 10 N NaOH was added 
drop wise until the solution turned clear.  As the solution cooled, 1 N HCl was added drop wise 
until the PFA solution reached pH 7.0, which was assessed using ColorpHast
®
 pH Test Stripe 
Non-Bleeding pH 0-14 test strips.  The final solution was made up to 100 mL using 1X PBS, 
sterilized using a 0.22 'm filter and stored at 4˚C up to one month. 
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Table 3:  List of Antibodies Used for Western Blot Analysis and Immunofluorescence. 
Each antibody was diluted as appropriate for its application.  Catalog numbers and suppliers are 
also indicated.  WB indicates Western Blot analysis; IF indicates immunofluorescence. 
 
Name Dilution Application Supplier 
Alexa Fluor
®
 488 Goat Anti-Mouse IgG (H+L) 
*
highly cross-adsorbed
*
 (A11029) 
1:200 IF Invitrogen 
Alexa Fluor
®
 594 Goat Anti-Mouse IgG (H+L) 
*
highly cross-adsorbed
*
 (A11032) 
1:200 IF Invitrogen 
Donkey Anti-Mouse IgG-HRP (sc-2314) 1:10000 WB Santa Cruz 
Goat Anti-Rabbit IgG-HRP (sc-2004) 1:10000 WB Santa Cruz 
Living Colors
®
 Rabbit Anti-DsRed (632496) 1:1000 WB Clontech 
Mouse Anti-Hemagglutinin Antibody (sc-7392) 1:1000 WB Santa Cruz 
Mouse Anti-SC35 (phospho) Nuclear Speckle 
Marker (ab11826) 
1:1000 IF Abcam 
Mouse Anti-"-Actin (sc-47778) 1:2000 WB Santa Cruz 
Rabbit Anti-C/EBP! (sc-61) 1:1000 WB Santa Cruz 
Rabbit Anti-CA150 (A300-360A) 1:2000 WB Bethyl Labs 
Rabbit Anti-TBP (sc-204) 1:1000 WB Santa Cruz 
 
 
3.7.2  Image Acquisition and Analysis 
 
 Prepared slides were imaged using an Olympus Fluoview 300 laser scanning confocal 
microscope (D. Mousseau, University of Saskatchewan) equipped with a blue Argon (488 nm, 
10 mW) and green Helium Neon (543 nm, 1 mW) laser.  Briefly, slides were inverted (cover 
slip side down), mounted using immersion oil at 60x objective (Plan-Apochromat 60XO/1.4), 
and viewed under fluorescence with the appropriate filter until a cell was selected for imaging.  
Once chosen, image acquisition was performed using 3-dimensional XYZ optical scanning 
through the thickness of the sample.  Pinhole diameter (aperture, 100 'm), laser power, 
photomultiplier tube, gain, and offset were set optimally to decrease background signals in the 
acquired image.  Additionally, sequential scanning, first green, then red, was selected for 
certain images to improve the resolution and quality of the red signal.  Once an appropriate Z-
section scan was chosen, an image was acquired using Kalman filtering (set at 6) at a slow scan 
speed (4.57 s/scan) for the best resolution. 
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4.  RESULTS 
 
 
4.1  TCERG1 Reverses Growth Arrest Activity of C/EBP! 
 
 TCERG1 is a modular protein containing multiple functional domains, therefore, it 
follows that one or more of these domains could be involved in TCERG1-mediated inhibition 
of C/EBP! activity.  Since TCERG1 has the ability to inhibit all activities of C/EBP!, both 
transcriptional and growth arrest, it is important to resolve which domains of TCERG1 are 
responsible for the inhibition of C/EBP! activity.  Recent results obtained using a proliferation 
assay examining a TCERG1 mutant consisting of only the carboxy-terminal domain (amino 
acids 641-1098) revealed that this domain lacks the ability to reverse growth arrest of cells, 
suggesting the functional or interaction domain(s) lies elsewhere (McFie et al., 2006). 
To further characterize the functional domain(s) that reside in TCERG1 responsible for 
reversing C/EBP! anti-proliferative activity, an assay was designed to both qualitatively and 
quantitatively assess TCERG1 inhibitory activity in COS7 cells.  The identification of growth-
arrested or actively proliferating cells was provided by the ectopic expression of EGFP, which 
can be observed in live cells using a fluorescence microscope.  Cells were visualized three days 
post-transfection and those expressing EGFP fluoresced throughout the cell, while cells 
expressing EGFP fused to the carboxy-terminal domain of C/EBP!, C/EBP!-EGFP, could be 
identified by the presence of green fluorescence restricted to the nuclei.  Although this type of 
assay was fairly challenging to develop, once established, the results were reproducible.  The 
transfection efficiency ranged from 40-60% using chemical methods, determined by 
comparison between green filter and bright field imaging using a fluorescence microscope.  
Also, controlling the initial dilution of cells and ensuring the majority were well separated 
single-cell colonies at the time of transfection dramatically decreased the occurrence of false 
positives (data not shown).  Finally, the advantage of this method is that only transfected and 
subsequent fluorescing cells are assayed unlike many commercially available proliferation kits 
that assay all cells regardless of transfection efficiency or initial confluency of cells, the latter 
often required at 80-90%. 
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 Growth arrest assays were initially performed in COS7 cells expressing TCERG1 and 
C/EBP!-EGFP individually to establish this assay in this cell line.  COS7 cells were chosen for 
several reasons; they express lower levels of endogenous TCERG1 relative to other cell lines 
previously examined in our laboratory (data not shown), cells proliferate in monolayers, and 
lastly, the cellular morphology of the cells make it easy to identify clusters of proliferating 
cells.  The cDNA obtained for TCERG1 was originally isolated from a vector coding for amino 
acids 32-1098 provided by M. Garcia-Blanco (Duke University), who also determined that the 
first 31 amino acids of TCERG1 were dispensable (Sune et al., 1997).  Therefore, TCERG1 32-
1098 was cloned in-frame into the pHA3 vector containing three-tandem hemagglutinin (HA3) 
epitopes fused to the amino terminal end of TCERG1.  In the case of C/EBP!, it has been 
previously demonstrated that EGFP fused to the amino terminal end of C/EBP! (EGFP-
C/EBP!) could still mediate growth arrest but was transcriptionally inactive (Schaufele et al., 
2001).  Therefore, the complementary C/EBP! carboxy-terminal end fusion to EGFP (C/EBP!-
EGFP), which retains all C/EBP! activities (Schaufele et al., 2001), was selected for all 
subsequent studies.  
COS7 cells were transiently transfected with appropriate vectors and were visualized 
three days post-transfection using a fluorescence microscope for cells expressing EGFP or 
C/EBP!-EGFP in the presence and absence of TCERG1 32-1098.  Figure 5 contains 
representative images obtained from growth arrest assays.  The first image in each panel 
represents the phase contrast view (greyscale), followed by an image obtained using a filter for 
green fluorescence.  The last image represents a merged image of the first two to verify the 
presence of clustered or single-cell colonies.  For each assay, a range of 140-160 individual cell 
colonies were counted per plate and categorized as single cells under growth arrest (Figure 5B) 
or proliferating cells characterized by the presence of colonies of two or more cells, 
respectively (Figure 5A and C).  A graphical representation of the results is found in Figure 6.  
In control assays, where EGFP alone was expressed, numerous clustered cells were identified 
and accounted for 71% of the cell colonies assessed.  Next, COS7 cells were transfected with 
plasmids encoding either C/EBP!-EGFP or TCERG1 32-1098 to show the effect of each 
protein on the proliferative capacity of the cells.  When C/EBP!-EGFP was expressed alone, 
only 18% of the colonies assessed were in clusters, demonstrating growth arrest of cells.  In 
contrast, COS7 cells overexpressing TCERG1 32-1098 were actively proliferating and 
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Figure 5.  Growth Arrest Assays to Examine the Ability of TCERG1 to Reverse C/EBP!-
Mediated Growth Arrest. 
COS7 cells were transiently transfected to express EGFP, C/EBP!-EGFP, or C/EBP!-EGFP 
plus TCERG1.  Cells were observed three days post-transfection using an inverted fluorescent 
microscope to qualitatively assess the proliferative capacity of cells as under growth arrest or in 
proliferating clusters.  Each panel from left to right consists of images using phase contrast, a 
green fluorescent filter, and the corresponding merged image.  Images were captured with a 
digital camera and modified using SPOT Advanced software.  (A)  Proliferation is observed as 
a cluster of cells that are visualized when TCERG1 is co-expressed with EGFP (green cells).  
(B)  Cells are observed as single cells under growth arrest upon the expression of C/EBP!-
EGFP (green nuclei) and in conditions where TCERG1 is unable to reverse C/EBP!-EGFP-
mediated growth arrest.  (C)  Reversal of C/EBP!-EGFP-mediated growth arrest in the 
presence of TCERG1 is observed as a cluster of green nuclei indicative of proliferation and 
confirmed by phase contrast imaging. 
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Figure 6.  The Amino-Terminal Domain of TCERG1 Reverses Growth Arrest Caused by 
C/EBP!. 
A. COS7 cells were transiently transfected with an expression vector for EGFP (control) alone 
and with various TCERG1 truncation mutants as indicated.  Between 140-160 individual green-
fluorescing colonies of two or more cells were visually identified and counted using a 
fluorescence microscope and are shown as a percentage.  B.  The percentage of proliferating 
cells expressing each TCERG1 truncation mutant in the presence of C/EBP!-EGFP.  Control 
indicates the percentage of cells proliferating when EGFP is expressed alone.  The values 
shown are the means ± standard error of at least three independent assays performed in 
duplicate. 
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contained 73% of colonies of clustered cells, similar to results obtained in control conditions 
(Figure 6A). 
 Once the above conditions were established, cells were transiently co-transfected with 
vectors expressing C/EBP!-EGFP and TCERG1 32-1098.  Consistent with previous studies, 
TCERG1 32-1098 was able to reverse C/EBP!-EGFP-mediated growth arrest of cells (McFie et 
al., 2006) indicated by the presence of 63% proliferating cell colonies, a difference of 45% 
relative to cells demonstrating growth arrest (Figure 6B, compare TCERG1 32-1098 to 
C/EBP!).  These results confirm the ability of TCERG1 to reverse C/EBP! anti-proliferative 
activity in COS7 cells. 
 
4.1.1  Generation of TCERG1 Truncation Mutants to Identify Region(s) Responsible for 
Inhibition of C/EBP! Growth Arrest Activity 
 
To determine which domain(s) within TCERG1 is responsible for the inhibition of 
growth-arrest by C/EBP!, several truncation mutants of TCERG1 were generated.  Each mutant 
was designed with careful consideration, with the deletion of specific modular domains 
suspected to be involved in the inhibition of growth arrest caused by C/EBP!.  An illustration 
of each TCERG1 mutant is provided in Figure 7 indicating the corresponding amino acids and 
the domains retained in each construct.  All mutants were cloned into a mammalian expression 
vector that linked three HA epitopes onto the amino-terminal end of the expressed protein.  In 
the case of TCERG1 641-1098 and 32-293, a nuclear localization signal (NLS) from the SV40 
large T-antigen was engineered onto the amino terminal end of TCERG1 immediately 
following the HA3 epitopes since the endogenous NLS was deleted. 
 Initially, protein expression for each TCERG1 truncation mutant was determined by 
Western Blot analysis prior to testing in growth arrest assays to ensure that the protein was 
being expressed and was of the expected size.  COS7 cells were transiently transfected with 
equal amounts of TCERG1 expression plasmid, cytosolic and nuclear extracts were prepared 
and analyzed using Western Blot analysis.  Each TCERG1 mutant was detected using 
antibodies to the hemagglutinin epitope fused to the amino-terminal end of the protein.  All 
TCERG1 mutants were detected in the nuclear fraction; however, TCERG1 32-668, 641-1098 
and 32-293 were also present in the cytosolic extracts (Figure 8).  The cytoplasmic population 
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Figure 7.  TCERG1 Truncation Mutants Used in This Study. 
TCERG1 is a 1098 amino acid nuclear protein.  The amino terminus contains three WW 
domains (purple), implicated in protein-protein interactions, and a unique glutamine-alanine 
(QA)38 repeat (teal) of unknown function.  The carboxy terminal domain consists of six FF 
domains (green), which, like WW domains, are involved in protein-protein interactions.  
TCERG1 also has a putative nuclear localization signal (NLS, red) located between the amino 
and carboxy terminal domains.  The amino acids contained in each mutant are stated on the left 
in parentheses and indicated in each illustration.  An SV40 large T-antigen NLS (yellow) was 
cloned in-frame to the amino terminus of TCERG1 641-1098 and 32-293 to replace the 
endogenous NLS that has been deleted as a result of its construction. 
 
 
of the latter two mutants could be partially explained by the loss of endogenous NLS and the 
fact that the SV40 NLS was not completely efficient or sufficient for nuclear targeting.  It is 
possible that certain regions have been removed that contribute to proper nuclear localization, 
thus resulting in a cytoplasmic pool.  However, using LSCM techniques to visualize TCERG1 
mutants fused to a red fluorescent protein, TCERG1 641-1098 was the only mutant that could 
be observed both in the cytoplasm and within the nucleus, while 32-668 and 32-293 were 
exclusively localized within the nucleus (Figure 8, bottom panel).  Inspection of levels of 
TCERG1 641-1098 and 32-293 protein detected by Western Blot analysis indicated that these 
two mutants were expressed at higher levels than 32-1098.  Due to the difference in expression 
levels, approximately half of the amount of plasmid for these two mutants was transfected in 
COS7 cells to account for protein expression variation.  Finally, all mutants migrated to a 
molecular weight comparable to the theoretical size predicted using Internet software
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Figure 8.  Protein Expression Profiles of HA3-TCERG1 Mutants in COS7 Cells. 
COS7 cells were transfected with each HA3-TCERG1 truncation mutant and cytosolic (C) and 
nuclear (N) extracts were prepared 24 h post-transfection.  Approximately 12.5 µg extract was 
loaded into and resolved in a 4% stacking/9% resolving SDS-polyacrylamide gel.  TCERG1 
mutants (indicated at the top) were detected using antibodies to the hemagglutinin epitope fused 
to the amino-terminal end of each mutant.  An arrow is used to mark the band corresponding to 
each each mutant as appropriate.  A molecular weight marker, in kilodaltons, is indicated on the 
left.  The bottom panel of images represents the localization of each TCERG1 expressed as a 
fusion protein to mCherry, which emits red fluorescence.  Images of COS7 nuclei, with the 
exception of TCERG1 641-1098 (entire cell), were captured using LSCM.  The magnification 
of each image varied depending on the size of the cell or nucleus.  Scale bar: 10 µm. 
 
 
(Walker, 2005).  The estimated size of each protein is as follows, in the order of appearance in 
the Western blot: 32-1098, 180 kDa; 641-1098, 65 kDa; 281-1098, 120 kDa; 32-293, 40 kDa; 
32-668, 100 kDa.  The predicted sizes of each protein including the HA3 epitope and NLS 
where appropriate are as follows: TCERG1 32-1098, 125 kDa; 641-1098, 60.6 kDa; 281-1098, 
95.5 kDa; 32-293, 33.5 kDa; 32-668, 73.5 kDa.  It is important to note that based on the amino 
acid sequence alone of full length TCERG1, software predicted the protein to be 124 kDa, even 
though TCERG1 was originally characterized and identified as a 150 kDa protein (Sune et al., 
1997).  Thus, the difference in size between the actual and predicted molecular weights could 
be a result of post-translational modification. 
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4.1.2  Amino-Terminal Domain of TCERG1 is Required to Reverse Growth-Arrested 
Cells 
 
Next, growth arrest assays were performed to examine the effect of various TCERG1 
truncation mutants for their ability to inhibit C/EBP!-mediated growth-arrested COS7 cells in 
an attempt to identify the region(s) within TCERG1 responsible for the inhibitory activity.  The 
initial TCERG1 mutants examined in growth arrest assays were based on previous studies 
postulating that the amino terminal portion of TCERG1 was important for reversing C/EBP!-
mediated growth-arrested cells (McFie et al., 2006).  Therefore, a mutant lacking the amino 
terminal domain was generated and designated TCERG1 641-1098 (Figure 7) in order to 
corroborate previous results showing that a similar mutant lacks inhibitory activity (McFie et 
al., 2006).  In addition to this, a mutant whose carboxy-terminus was deleted, TCERG1 32-668, 
was also generated and examined on the premise that this mutant would retain the functional 
domain(s) required for TCERG1 inhibitory activity.  Both TCERG1 mutants were examined for 
the ability to reverse C/EBP!-mediated growth arrest of COS7 cells.  Results of each assay are 
summarized in Figure 6.  All assays were initially performed with each TCERG1 mutant alone 
as a control to assess whether the expression of the TCERG1 mutant had any effect on the 
proliferative capacity of COS7 cells.  Initial test conditions in cells expressing TCERG1 641-
1098 or TCERG1 32-668 resulted in the identification of 73-74% proliferating cell colonies, 
comparable to TCERG1 32-1098 (73%; Figure 6A).  This indicated that there were no 
apoptotic or anti-proliferative effects in COS7 cells related to the expression of each mutant.  
Next, cells were transiently transfected to co-express each TCERG1 mutant and C/EBP!-EGFP 
and were visually assessed three days later.  Similar to previous observations (McFie et al., 
2006), results of the growth arrest assays confirmed that the carboxy-terminal portion of 
TCERG1 (641-1098) was unable to reverse growth arrest as 75% individual cell colonies 
remained single celled (Figure 6B).  Furthermore, in assays examining TCERG1 32-668, 61% 
of cells were identified as clusters, levels similar to that achieved by TCERG1 32-1098 (Figure 
6B).  These results further support the hypothesis that the functional portion of TCERG1, with 
respect to reversing the anti-proliferative activity of C/EBP!, lies within the amino terminal 
domain. 
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In order to investigate which domains within the amino terminus may contribute to this 
activity, two additional mutants were generated.  TCERG1 32-293 contains the first WW 
domain and the unique QA repeat, and TCERG1 281-1098 contains WW2 and WW3 in 
addition to all six FF domains (Figure 7).  Control experiments in conditions where each mutant 
was expressed in the absence of C/EBP!-EGFP showed no effect on the proliferative capacity 
of COS7 cells relative to EGFP or TCERG1 32-1098, with 66-70% cell colonies identified in 
clusters (Figure 6A).  Growth arrest assays were then performed in the presence of C/EBP!-
EGFP and results indicated that TCERG1 32-293 and 281-1098 were unable to successfully 
revert growth-arrested cells to a proliferative capacity as indicated by 29% and 28% clustered 
cells, respectively (Figure 6B).  These findings were similar to that observed with TCERG1 
641-1098, which lacks the amino-terminal region entirely.  This suggested that these mutants 
lack the domain(s) within the amino-terminus necessary for inhibitory activity and that multiple 
domains in this region may be required for this activity.  Therefore, based on the collective 
results from growth arrest assays, amino acids 32-668 are required and sufficient for the 
inhibition of growth arrest of COS7 cells, and multiple domains in this region may be involved. 
 
 
4.2  Spatial Distribution of TCERG1 and C/EBP! in COS7 Cells 
 
 The discovery that the nucleus is a complex organelle consisting of subcompartments 
arranged into discrete functional domains has created a new area of research devoted to 
investigating the dynamic environment within the nucleus (Matera, 1999; Misteli, 2001; Wang 
et al., 2002b; Corry and Underhill, 2005).  As such, evidence from various elegant studies 
suggests that components of many nuclear bodies have the ability to redistribute to areas of 
active transcription and/or sites where splicing events occur (Bregman et al., 1995; Misteli et 
al, 1997; Melcak et al, 2000; Phair and Misteli, 2000; Misteli 2001, 2008b; Corry and 
Underhill, 2005; Demarco et al, 2006; Gorski et al, 2006).  This theory led to the hypothesis 
that TCERG1 may translocate to sites occupied by C/EBP!, such as in transcription factories, 
where it can act to prevent C/EBP! transcriptional activity.  Likewise, TCERG1 could 
sequester C/EBP! away from transcriptionally active sites to splicing factor-rich nuclear 
speckles.  Thirdly, TCERG1 may recruit C/EBP! to other nuclear bodies where C/EBP! has no 
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activity, thereby altering the localization of both proteins.  Finally, TCERG1 may relocalize to 
functional compartments that act as storage sites for C/EBP!, thereby preventing translocation 
of C/EBP! to transcriptionally active sites or domains required for C/EBP!-mediated activity.  
Therefore, we set out to examine if the ectopic expression of TCERG1 had any effect on the 
subnuclear distribution of C/EBP! or vise versa. 
Fluorescent fusion proteins and immunostaining techniques using fluorophores in 
combination with LSCM are widely used to examine localization of proteins in cells (Iborra et 
al., 2003).  Selecting fluorophores with non-overlapping excitation and emission spectra allows 
one to visually characterize alterations in localization patterns.  Furthermore, images acquired 
using z-axis optical scanning techniques provide fine detail that can detect subtle differences in 
the spatial distribution of different proteins.  In the studies presented here, utilization of 
fluorescent fusion proteins was chosen as the preferred method of subnuclear localization 
analysis instead of immunostaining strategies for several reasons.  First, all previous studies 
examining the subnuclear localization of C/EBP! were performed with fusion proteins (Tang 
and Lane, 1999; Schaufele et al., 2001, 2003; Zhang et al., 2001; Liu et al., 2002; Day et al., 
2003; Enwright et al., 2003; Demarco et al., 2006).  Second, indirect immunostaining 
techniques using secondary antibodies conjugated with fluorophores can result in non-specific 
binding and subsequent background signal that can generate images that are not well defined or 
are difficult to detect (data not shown).  Additionally, antibody dilution for fine particle and co-
localization studies require considerable fine-tuning (Mintz and Spector, 2000).  Although 
using fluorescent fusion proteins leads to lower levels of expression relative to non-
fluorophore-tagged proteins, newly accumulated protein deposits can be observed by a direct 
means that is not possible with immunofluorescence, which relies on the indirect detection of 
the protein of interest. 
The expression plasmid encoding C/EBP!-EGFP used in growth arrest assays was also 
used for co-localization studies.  EGFP has an excitation/emission spectrum of 488 nm and 507 
nm, respectively.  mCherry, a red fluorescent protein, was selected as the contrasting fusion 
protein for TCERG1 and its mutants.  mCherry is a variation of Discosoma striata (DsRed) that 
is monomeric and has several modifications to enhance protein expression (Shaner et al., 2004).  
It has an excitation/emission spectrum of 587 nm and 610 nm, respectively.  Each TCERG1 
mutant was cloned in-frame such that mCherry was fused to the amino-terminal region of the 
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Figure 9.  Expression Analysis of mCherry-TCERG1 Mutants. 
COS7 cells were transfected with mCherry or mCherry-TCERG1 truncation mutant and 
extracts were prepared 24 hours post-transfection.  The expression of each mCherry-TCERG1 
truncation mutant (indicated above) was detected by immunoblot analysis of prepared cytosolic 
(C) and nuclear (N) extracts (15 µg).  Protein extracts were detected using an antibody to 
DsRed which also recognizes mCherry.  TBP (43 kDa) was also detected to serve as a loading 
control for the presence of nuclear proteins.  Arrows indicate the overexpressed mCherry-
TCERG1 proteins where appropriate and molecular weight markers, in kilodaltons, are shown.  
Estimated protein sizes are as follows: mCherry, 30 kDa; TCERG1 32-1098, 180 kDa; 32-668, 
110 kDa; 281-1098, 120 kDa; 641-1098, 80 kDa.  The bottom panel shows images obtained by 
LSCM of COS7 cells expressing the corresponding mCherry or mCherry-TCERG1 mutant.  
mCherry and mCherry-TCERG1 641-1098 represent whole cells, and TCERG1 32-1098, 32-
668 and 281-1098 are detected in the nuclei of COS7 cells.  Scale bars have been equalized to 
10µm to account for different magnifications. 
 
resulting polypeptide.  The integrity of the open reading frame for each mutant was verified by 
DNA sequencing and each mutant was expressed in COS7 cells to assess protein expression. 
Cytosolic and nuclear extracts were prepared, resolved by Western Blot analysis and 
detected using an antibody to DsRed (Figure 9).  mCherry is approximately 30 kDa and was 
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primarily expressed in the cytosol whereas mCherry-TCERG1 32-1098 (actual size: 180 kDa, 
predicted size: 148 kDa) was predominantly expressed in the nucleus.  The expression of the 
transcription factor TBP was used as a control for nuclear protein verification.  The expression 
of the remaining mCherry-TCERG1 mutants: 32-668, 120 kDa ; 641-1098, 90 kDa; and 281-
1098, 140 kDa (predicted sizes: 96 kDa, 84.5 kDa, and 122 kDa, respectively), with the 
exception of 32-293 which was not detected, were also present in the cytosolic fraction.  
However, apart from mCherry-TCERG1 641-1098, no fluorescence could be observed in the 
cytoplasm of cells when visualized by LSCM, including 32-293 (Figure 9, bottom panel).  
Finally, although modifications have been made to improve levels of mCherry-fusion protein 
expression (Shaner et al., 2004), it may have played a factor in the expression and stability of 
mCherry-TCERG1 32-1098, resulting in lower levels of expression relative to the other 
mutants.  The size and length of the fusion protein may also play a factor in its reduced 
expression.  Therefore, the quantity of plasmid DNA transfected for each TCERG1 truncation 
mutant for co-localization studies was adjusted such that each mutant was similarly expressed 
relative to TCERG1 32-1098. 
It has been established that C/EBP! and TCERG1 localize to different compartments 
within the nucleus, although both populate non-nucleolar regions (Tang and Lane, 1999; Zhang 
et al., 2001; Sanchez-Alvarez et al., 2006).  Endogenous and ectopic expression of C/EBP! 
generally localize to distinct punctate foci occupied by heterochromatin, as demonstrated in a 
variety of murine-derived cell lines (Tang and Lane, 1999; Schaufele et al., 2001; Zhang et al., 
2001).  Conversely, TCERG1 localizes to a functionally and structurally different subnuclear 
compartment termed splicing factor-rich nuclear speckles (Sanchez-Alvarez et al., 2006), 
characterized by the functional constituents localized within these discrete domains (Fu and 
Maniatis, 1990).  Additionally, a small population of TCERG1 has been observed throughout 
non-nucleolar regions of the nucleoplasm (Sanchez-Alvarez et al., 2006).  Therefore, it was 
essential to show that both C/EBP! and TCERG1 localize to their respective nuclear bodies in 
COS7 cells, as this is the first time these studies were performed in this cell type.  COS7 cells 
were first co-transfected with vectors encoding fluorescent proteins, fixed, and prepared for 
visualization using LSCM.  In control experiments expressing either EGFP or mCherry, each 
protein localized diffusely throughout the cell with no apparent pattern (Figure 10A).  In 
contrast, C/EBP!-EGFP and mCherry-TCERG1 32-1098 appeared to localize to different but 
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distinguishable patterns within the nucleus.  C/EBP!-EGFP generally localized to large 
globular foci that number between 20-50 per cell and was absent from the nucleoli.  
Additionally, it should be noted that in COS7 cells, C/EBP!-EGFP adopted about five distinct 
subnuclear patterns, which could be attributed to various stages of the cell cycle since the cells 
were not synchronized (see section 4.2.1.1).  The pattern shown in Figure 10A appeared in 
approximately 75% of the cells observed in this study, and therefore was chosen as the primary 
localization of C/EBP!-EGFP in COS7 cells.  In contrast, mCherry-TCERG1 32-1098 
principally localized to less distinct, relatively large subnuclear foci that were granular in 
nature, reminiscent of nuclear speckles (Figure 10A).  Additionally, there was a less 
concentrated, more dispersed population throughout the nucleoplasm but was excluded from 
the nucleolus, consistent with observations in other cell lines (Sanchez-Alvarez et al., 2006).  
Since there has only been one publication examining the subnuclear localization of TCERG1, it 
was necessary to determine if the pattern observed in COS7 cells corresponded to nuclear 
speckles.  SC35 is well established as a nuclear speckle marker (Fu and Maniatis, 1990; Hall et 
al., 2006), therefore if TCERG1 indeed localized to these nuclear subcompartments, 
considerable overlap between the two should be observed.  Thus, cells were transiently 
transfected with pmCherry-TCERG1 32-1098 and prepared for indirect immunofluorescence to 
detect the endogenous SC35 prior to imaging. The subnuclear speckle pattern was observed for 
both SC35 (green) and TCERG1 32-1098 (red) and was confirmed by the complete overlap 
between the two, demonstrated by areas of yellow colour (Figure 10B, merge).  These results 
suggest that TCERG1 localizes to splicing factor-rich nuclear speckles in COS7 cells. 
 
4.2.1  TCERG1 Co-Localizes with C/EBP! 
 
If the inhibition of C/EBP! by TCERG1 occurs through a general mechanism involving 
nuclear retention or by inducing a redistribution of C/EBP! from sites of active transcription, 
LSCM can be used as a tool to examine the subnuclear distribution patterns when both 
TCERG1 and C/EBP! are co-expressed.  Therefore, to investigate if the localization pattern of 
either protein could be influenced by the co-expression of the other, cells were transiently co-
transfected with expression vectors for C/EBP!-EGFP and mCherry-TCERG1 32-1098 and 
prepared for imaging using LSCM.  Remarkably, the subnuclear pattern of mCherry-TCERG1 
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Figure 10.  TCERG1 Co-Localizes with C/EBP! in COS7 Cells. 
COS7 cells were transiently transfected with vectors expressing either enhanced green 
fluorescent (EGFP, green) or mCherry (red) proteins and visualized using an Olympus 
FluoView 300 laser scanning confocal microscope under 60x oil immersion.  Images were 
collected by Z-sectioning using software provided with the microscope.  A 10 µm scale is 
indicated where appropriate and have been adjusted accordingly based on magnification.  With 
the exception of EGFP and mCherry, all images represent COS7 cell nuclei  (A)  Localization 
of EGFP, mCherry, C/EBP!-EGFP, mCherry-TCERG1 32-1098, and EGFP-Sp1 controls.  (B)  
Detection of SC35, a nuclear speckle marker, using conjugate Alexa Fluor# 488 antibody 
(green) and its overlap with mCherry-TCERG1 32-1098 (merge, shown in yellow).  (C)  Co-
expression of C/EBP!-EGFP and mCherry-TCERG1 32-1098.  (D)  Expression of mCherry-
TCERG1 32-1098 and EGFP-Sp1, a non-specific transcription factor for TCERG1 activity 
(McFie et al., 2006). 
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32-1098 was drastically altered and localized to distinct globular punctate foci.  Moreover, the 
localization of TCERG1 completely overlapped with C/EBP!-EGFP indicated by regions of 
yellow, strongly suggesting that these two proteins co-localized (Figure 10C, merge).  To 
confirm the specificity of the co-localization between C/EBP!-EGFP and mCherry-TCERG1, 
COS7 cells were transiently transfected with plasmids to express EGFP fused to Sp1, a 
transcription factor previously shown not to interact with TCERG1 (McFie et al., 2006), in the 
absence and presence of mCherry-TCERG1 32-1098.  Ectopic expression of EGFP-Sp1 
predominantly localized in a heterogeneous non-nucleolar pattern with a subpopulation 
concentrated in 5-20 small punctate foci (Figure 10A), similar to results obtained by Moorefield 
et al. (2006) in COS1 cells.  Next, cells co-expressing EGFP-Sp1 and mCherry-TCERG1 32-
1098 were assessed for alterations in spatial distribution of either protein.  Images obtained 
from LSCM indicated that EGFP-Sp1 had no effect on the subnuclear localization of mCherry-
TCERG1 or vise versa, and that TCERG1 remained localized to splicing factor-rich nuclear 
speckles (Figure 10D).  These results provided strong evidence to show that the redistribution 
of mCherry-TCERG1 32-1098 to distinct punctate foci occupied by C/EBP!-EGFP occurs 
specifically upon the co-expression of C/EBP!-EGFP.  Finally, different amounts of EGFP-
C/EBP! and mCherry-TCERG1 32-1098 were co-transfected individually and together, and 
although there was some cell-to-cell variation, the level of protein expression did not affect 
subnuclear distribution of either protein (data not shown).  This demonstrates that the 
concentration of TCERG1 and C/EBP! with respect to protein mobility and accessibility was 
not a factor in the co-localization studies. 
 
4.2.1.1 TCERG1 Localizes to Areas Occupied by C/EBP! Regardless of Initial C/EBP! 
Pattern 
 
 During the investigation of the subnuclear localization of C/EBP! by LSCM, it was 
discovered that C/EBP! adopted five distinct patterns within the nucleus of COS7 cells (Figure 
11).  Of the five, C/EBP! primarily localized in well-defined globular punctate foci in roughly 
75% of the cells, and was dispersed throughout the nucleoplasm in about 10-15% of cells 
visualized (Figure 11A and B).  In the remaining 10-15% of cells expressing C/EBP!, three 
distinct patterns were observed: stippled, dispersed with areas of non-uniform accumulation, 
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Figure 11.  TCERG1 Co-Localizes with C/EBP! Regardless of Subnuclear Distribution. 
COS7 cells were transfected with expression vectors encoding C/EBP!-EGFP and mCherry-
TCERG1 32-1098.  Cells were fixed and prepared for visualization using a laser scanning 
confocal microscope as described in materials and methods.  C/EBP! (green) displays several 
different subnuclear localization patterns in unsynchronized COS7 cells (A-E).  TCERG1 32-
1098 (red) is shown in the middle panel and the following merged image of C/EBP! and 
TCERG1 where overlap is indicated by the presence of a yellow colour, shown on the right.  
Scale bars have been normalized to 10 µm to account for different magnifications.
could provide evidence for the domain(s) essential for co-localization with C/EBP!. 
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and diffuse with 5-10 small punctate foci (Figure 11C-E, respectively).  Due to the different 
localization patterns adopted by C/EBP!-EGFP, it was questioned if the marked redistribution 
of TCERG1 was a result of a particular subnuclear occupancy of C/EBP!-EGFP.  Remarkably, 
regardless of the subnuclear residence of C/EBP!-EGFP, mCherry-TCERG1 32-1098 appeared 
to co-localize with C/EBP! as evidenced by the abundant yellow colour displayed in the 
merged image (Figure 11A-E).  This demonstrated that the co-localization between these two 
proteins is consistent and independent of the initial pattern of subnuclear localization adopted 
by C/EBP!-EGFP in COS7 cells. 
 
 
4.3  The Amino-Terminal Domain of TCERG1 is Required for Co-Localization with 
C/EBP! in COS7 Cells 
 
Based on results showing that an intact amino-terminus of TCERG1 was required and 
sufficient to reverse C/EBP!-mediated growth arrest (see Figure 6 and section 4.1.2) and 
transcriptional activity (McFie et al., 2006), it was questioned if this domain was important for 
co-localization with C/EBP!.  If the subnuclear localization of C/EBP! is a consequence of its 
activity and the ability of TCERG1 to inhibit the activities requires co-localization with 
C/EBP!, then mutants with the ability to inhibit C/EBP! activity should also occupy the same 
nuclear domains as C/EBP!.  Thus, loss of TCERG1 translocation in the presence of C/EBP! 
could provide evidence for the domain(s) essential for co-localization with C/EBP!.
First, LSCM co-localization studies were performed to assess the nuclear distribution of 
each mCherry-TCERG1 truncation mutant in the absence of C/EBP!-EGFP.  With the 
exception of mCherry-TCERG1 32-668 and 641-1098, the other mutants, mCherry-TCERG1 
32-1098, 32-668 and 281-1098, localized in a pattern reminiscent of splicing factor-rich nuclear 
speckles (Figure 12A).  Although absent from the nucleolus, the spatial distribution of 
mCherry-TCERG1 32-668 was notably different than that of mCherry-TCERG1 32-1098.  It 
appeared to be reticular with no particular pattern or roughly defined foci and was randomly 
distributed throughout the nucleus.  Also, mCherry-TCERG1 641-1098 did not completely 
localize to the nucleus, as confirmed by both direct visualization (Figure 12A) and Western blot 
analysis (Figure 9), suggesting that the SV40 NLS was not sufficient for the complete and 
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Figure 12.  Subnuclear Localization of TCERG1 Truncation Mutants When Co-
Expressed with C/EBP! in COS7 Cells. 
Studies were performed in COS7 cells transiently transfected with vectors encoding fluorescent 
proteins, mCherry and EGFP, fused to TCERG1 (red) or C/EBP! (green), respectively.  (A) 
Subnuclear distribution of each TCERG1 truncation mutant as indicated.  (B-E) Co-expression 
of each TCERG1 truncation mutant with C/EBP! to examine their nuclear distrbution patterns.  
Each panel represents images of C/EBP!, TCERG1 mutants, and finally the merged image of 
the first two.  Images were captured by Z-sectioning using an Olympus FV300 confocal 
microscope under 60x oil objective.  A scale bar representing 10 µm based on the magnification 
is indicated in the bottom right of each image or panel where appropriate. 
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proper trafficking to the nucleus.  Additionally, this mutant was localized within several 
distinguishable populations throughout the cell.  mCherry-TCERG1 641-1098 mainly localized 
within the nucleus, both in an evenly dispersed pattern throughout the nucleoplasm and also in 
highly concentrated areas within the nucleolus or nucleoli of cells.  Several bright globular foci 
in the cytoplasm were also present near to and adjacent to the nuclear periphery when this 
mutant was expressed.  Regardless of the differences in subnuclear localization, and since 
mCherry-TCERG1 32-1098 was able to co-localize with C/EBP! independent of the initial 
nuclear residency of C/EBP! (see Figure 11), all mutants were examined for any pattern 
alterations in the presence of C/EBP!-EGFP.  Much like with mCherry-TCERG1 32-1098, 
mCherry-TCERG1 32-668 completely co-localized with C/EBP!-EGFP despite its different 
localization pattern in the absence of C/EBP!-EGFP (Figure 12B).  These results are intriguing 
because it demonstrates that localization of mCherry-TCERG1 32-668 to nuclear speckles was 
not required for nuclear translocation in the presence of C/EBP!-EGFP.  Moreover, this led to 
the proposal that TCERG1 mutants with the ability to interact with or function to inhibit the 
activities of C/EBP! should also co-localize with C/EBP!, regardless of their initial subnuclear 
residence.  This idea was confirmed by the results obtained for mCherry-TCERG1 641-1098, a 
mutant lacking the ability to reverse growth arrest (see Figure 6B), having no overlap with the 
distribution pattern of C/EBP!-EGFP (Figure 12C).   Surprisingly, mCherry-TCERG1 mutants 
32-293 and 281-1098, shown to have reduced ability to reverse growth arrest, also failed to 
completely co-localize with C/EBP!-EGFP (Figure 12D and E).  However, partial co-
localization indicated by areas of yellow in the merged image between these two mutants and 
C/EBP!-EGFP could be a result of limited interaction or decreased affinity to bind to C/EBP!, 
resulting from the deletion of critical regions required for co-localization and/or inhibitory 
activity toward C/EBP!.  Furthermore, the lack of significant co-localization between C/EBP!-
EGFP and either TCERG 32-293 or 281-1098 may result in the inability of the TCERG1 
mutants to inhibit C/EBP!-EGFP-mediated growth arrest.  This suggests that co-localization 
between TCERG1 and C/EBP! at sites occupied by C/EBP! is necessary to inhibit growth 
arrest.  Collectively, an intact amino-terminal domain of TCERG1 is sufficient to inhibit 
C/EBP! activity and contains domains important for proper co-localization with C/EBP!. 
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4.4  Subnuclear Localization of TCERG1 and C/EBP! is Not Cell-Type Specific 
 
 In order to examine whether C/EBP!-mediated sequestration of TCERG1 to foci 
occupied by C/EBP! was cell-specific, co-localization experiments were repeated in HEK293T 
cells.  Previous evidence supports that the amino terminal domain of TCERG1 contains 
functional motif(s) required for TCERG1-mediated inhibition of C/EBP! growth arrest and 
transcriptional activity in HEK293T cells (McFie et al., 2006).  To further support the 
hypothesis that the mechanism for TCERG1 inhibitory activity toward C/EBP! involved 
subnuclear sequestration, it was necessary to corroborate studies performed in COS7 cells by 
repeating these studies in a different cell line. 
 
4.4.1  TCERG1 Redistributes to Subnuclear Structures Occupied by C/EBP! in 
HEK293T Cells 
Co-localization studies in HEK293T cells were performed identically to those in COS7 
cells.  Upon the ectopic expression of EGFP or mCherry, each fluorescent protein was 
dispersed throughout the cell, similar to observations made in COS7 cells (compare Figure 10A 
and Figure 13A).  The expression of C/EBP!-EGFP was noticeably different in HEK293T cells 
than in COS7 cells and was the only consistent pattern observed throughout the studies.  More 
specifically, there were two non-nucleolar subpopulations of C/EBP!-EGFP observed within 
the nucleus: evenly dispersed throughout and highly concentrated within 5-10 distinct small 
foci (Figure 13A).  Conversely, the subnuclear distribution of mCherry-TCERG1 32-1098 was 
similar to that observed in COS7 cells and strongly overlapped with SC35, indicative of 
splicing factor-rich nuclear speckle occupancy (Figure 13A and B). 
Next, HEK293T cells were co-transfected with expression vectors for C/EBP!-EGFP 
and mCherry-TCERG1 32-1098 in order to examine the co-localization between the two 
proteins (Figure 13C).  Ectopic expression of mCherry-TCERG1 32-1098 in the presence of 
C/EBP!-EGFP caused a complete co-localization of mCherry-TCERG1 32-1098 with C/EBP!-
EGFP (Figure 13C).  Next, mCherry-TCERG1 32-1098 was co-expressed with EGFP-Sp1 to 
show the alteration in TCERG1 localization was specifically influenced by C/EBP!-EGFP and 
not with other transcription factors.  When expressed alone or in the presence of mCherry-
TCERG1 32-1098, EGFP-Sp1 showed a dispersed pattern that was absent from the nucleoli 
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Figure 13.  C/EBP! Alters the Subnuclear Localization of TCERG1 in HEK293T Cells. 
Transfected HEK293T cells expressing C/EBP!-EGFP and mCherry-TCERG1 32-1098 were 
prepared and assessed for the subnuclear distribution pattern of each protein.  A scale bar 
representing 10 µm is indicated as appropriate based on magnification for each collection of 
images.  (A)  Cellular distribution pattern of enhanced green fluorescent protein and mCherry 
(red).  Subnuclear localization of C/EBP!-EGFP, mCherry-TCERG1 32-1098, and EGFP-Sp1 
have been included as controls.  (B)  Cells expressing mCherry-TCERG1 32-1098 were 
assessed for localization to splicing factor-rich nuclear speckles using endogenous SC35 as a 
marker protein detected by indirect immunostaining technique (anti-SC35, 1:1000; green).  
Areas of complete overlap between the proteins are indicated by a yellow colour in the merged 
image to the right.  (C)  Nuclear distribution of mCherry-TCERG1 32-1098 upon co-expression 
of C/EBP!.  (D)  Localization of mCherry-TCERG1 32-1098 upon the co-expression of 
transcription factor EGFP-Sp1, a previousy established negative control for TCERG1 activity 
(McFie et al., 2006). 
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(Figure 13A and D).  As observed in COS7 cells, there was virtually no overlap between the 
nuclear localization patterns of EGFP-Sp1 and mCherry-TCERG1 32-1098 in HEK293T cells 
(Figure 13D, merge panel).  Thus, EGFP-Sp1 had no effect on the spatial distribution of 
mCherry-TCERG1 32-1098.  Moreover, mCherry-TCERG1 32-1098 was unable to influence 
the subnuclear distribution of EGFP-Sp1, as expected since TCERG1 neither interacts with nor 
affects Sp1 transcriptional activity (McFie et al., 2006).  Therefore, the striking alteration in the 
subnuclear localization of TCERG1 by C/EBP!-EGFP was not of a general nature nor an 
artifact of fluorescent-fusion protein expression.  The results obtained from the co-localization 
studies in HEK293T and COS7 cells reveal that subnuclear sequestration of TCERG1 to sites 
occupied by C/EBP! is specific but not cell-type dependent. 
 
 
4.5  The Amino-Terminus of TCERG1 Contains Domain(s) Essential for Subnuclear 
Translocation by C/EBP! 
 
To further validate the effects of C/EBP! on TCERG1 localization observed in COS7 
cells, the next step was to assess the nuclear patterns observed upon co-expression of C/EBP! 
and various TCERG1 truncation mutants in HEK293T cells.  If the effect of C/EBP! on 
TCERG1 subnuclear distribution is not cell-type specific and the mechanism by which this 
occurs is independent of the initial nuclear location of TCERG1, co-expression with C/EBP!, 
should yield similar results as that observed in COS7 cells.  First, each mCherry-TCERG1 
truncation mutant was expressed individually in order to evaluate its subnuclear distribution in 
HEK293T cells (Figure 14).  With the exception of mCherry-TCERG1 641-1098 and 32-668 
roughly defined large foci reminiscent of nuclear speckles were detected throughout the 
nucleoplasm but absent from the nucleolus.  mCherry-TCERG1 641-1098 also had a significant 
cytoplasmic pool, suggesting that it did not properly partition to the nucleus and was partially 
retained in the cytosol.  mCherry-TCERG1 32-668 had a more heterogeneous and irregularly 
dispersed appearance with no specific localization pattern apart from its exclusion from the 
nucleoli.  The localization pattern for each mutant resembled those found in COS7 cells and 
therefore appeared consistent between cell types.  Next, HEK293T cells were visually 
characterized following the co-expression of C/EBP!-EGFP and each mCherry-TCERG1 
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Figure 14.  Co-localization of TCERG1 Mutants and C/EBP! in HEK293T cells. 
HEK293T cells were co-transfected with mammalian expression vectors encoding fluorescent 
fusion proteins to C/EBP! (EGFP, green) and TCERG1 truncation mutants (mCherry, red).  
Cells were prepared and observed using LSCM.  Images of HEK293T cell nuclei were 
collected as described in materials and methods.  A scale bar of 10 µm is indicated as 
appropriate equalized to the magnification used.  (A)  Nuclear distribution of each mCherry-
TCERG1 mutant in the absence of C/EBP!-EGFP.  A significant cytosolic population is 
observed for mCherry-TCERG1 641-1098 in addition to nuclear localization.  (B-E)  Nuclear 
localization pattern upon co-expression of C/EBP!-EGFP and mCherry-TCERG1 truncation 
mutants.  Areas that appear yellow in the merged image indicate an overlap between the 
localization patterns of each protein. 
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mutant.  mCherry-TCERG1 32-668 was the only mutant that completely localized to areas 
occupied by C/EBP!-EGFP (Figure 14B) and virtually no overlap occurred between mCherry-
TCERG1 641-1098 and C/EBP!-EGFP (Figure 14C), remarkably similar to results obtained in 
COS7 cells.  More specifically, 641-1098 localized to areas within the nucleus completely 
devoid of C/EBP!-EGFP.  Moreover, mCherry-TCERG1 truncation mutants 32-293 and 281-
1098, which lack potentially important functional motifs, only partially overlapped with areas 
occupied by C/EBP!-EGFP (Figure 14D and E).  Therefore, results from co-localization studies 
performed in HEK293T and COS7 cells reveal the incredible ability of TCERG1 to strongly 
associate with C/EBP!-occupied subnuclear domains and that specific regions within TCERG1 
are important for this association. 
 
 
4.6  TCERG1 Does Not Co-Localize with C/EBP" 
 
 Although our laboratory has worked most extensively to investigate the effect of 
TCERG1 on C/EBP! activity, recent results showed that TCERG1 also has an inhibitory effect 
on the transcriptional activity of another C/EBP isoform, C/EBP" (McFie et al., 2006).  Using 
reporter gene assays, McFie et al. (2006) demonstrated that TCERG1 inhibited the 
transactivation potential of C/EBP".  Furthermore, TCERG1 inhibited the transactivation of 
C/EBP" in the presence of transcriptional co-activation, p300.  This suggests that TCERG1 has 
a dominant effect over p300-mediated activation of C/EBP" transcriptional activity (McFie et 
al., 2006).  Based on these data, it is possible that TCERG1 associates with C/EBP" and 
subnuclear localization may be involved in the inhibition of C/EBP" activity by TCERG1.  
Because of the marked relocalization of TCERG1 to co-localize with C/EBP!, we sought to see 
if the same effect could be observed in the presence of C/EBP".  First, EGFP-C/EBP" was 
expressed alone in both COS7 and HEK293T cells to characterize its nuclear pattern in each 
cell line (Figure 15).  The observations made of EGFP-C/EBP" were indistinguishable from 
those made with C/EBP!-EGFP in that both proteins localized in a similar globular punctate 
pattern (compare Figure 10A with Figure 15A), while it was distributed in a more dispersed 
pattern with a small number of areas enriched with protein in HEK293T cells (compare Figure 
13A with Figure 15C).  Control experiments showing the expression of mCherry- TCERG1 32- 
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Figure 15. C/EBP!  and TCERG1 Do Not Co-Localize in COS7 or HEK293T cells. 
COS7 and HEK293T cells were transfected with EGFP-C/EBP! (green) and mCherry-
TCERG1 32-1098 (red) and slides were prepared as described.  A scale bar is shown where 
appropriate.  (A-B)  Nuclei of COS7 cells showing the nuclear localization pattern of EGFP-
C/EBP! and mCherry-TCERG1 32-1098 expressed individually (A) and together (B) in COS7 
cells.  A merged image is shown to display the overlap between EGFP-C/EBP! and mCherry-
TCERG1 32-1098.  (C-D)  Subnuclear distribution of EGFP-C/EBP! and mCherry-TCERG1 
32-1098 in the nuclei of HEK293T cells expressed separately (C) and together (D). 
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1098 displayed the typical nuclear speckle pattern characterized by the presence of large 
roughly shaped foci and a smaller dispersed population throughout the nucleoplasm.  
Additionally, all proteins expressed in these studies were absent from both nucleolar and 
cytoplasmic regions. 
Next, COS7 and HEK293T cells were co-transfected with expression vectors encoding 
EGFP-C/EBP" and mCherry-TCERG1 32-1098 and prepared for visual examination by LSCM 
(Figure 15B and D).  Image analysis revealed that mCherry-TCERG1 32-1098 was retained in 
nuclear speckles and partially co-localized with regions occupied by EGFP-C/EBP" in both 
cells lines, indicated by the lack of yellow colour generated in the merged image.  These results 
indicate that EGFP-C/EBP" had no influence on the nuclear distribution of mCherry-TCERG1 
32-1098, in striking contrast to C/EBP!. 
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5.  DISCUSSION 
 
It was recently discovered that TCERG1 interacts with and co-represses C/EBP! 
activity (McFie et al., 2006).  Using various biochemical techniques, TCERG1 was shown to 
repress both the transcriptional and growth arrest activities of C/EBP!.  Interestingly, it was 
found that C/EBP! mediated these activities through different domains, suggesting that 
TCERG1 may act in a global manner to repress all forms of C/EBP! activity.  Results of the 
studies presented here further characterize TCERG1-mediated inhibition of C/EBP! growth 
arrest activity by investigating the domain(s) within TCERG1 that mediate this effect and 
provide evidence for a general mechanism by which this activity occurs.  In addition, results 
from LSCM provide compelling evidence that links subnuclear localization with the inhibition 
of C/EBP! growth arrest activity by TCERG1.  Collectively, these findings suggest this activity 
is mediated through the amino-terminal region of TCERG1 and possibly requires the additive 
effects of certain WW domains found within this domain.  This work supports a model has been 
proposed for the TCERG1-dependent inhibition of C/EBP!-mediated activity involving a 
subnuclear retention mechanism. 
 
 
5.1  The Amino-Terminal Domain of TCERG1 is Sufficient for Inhibiting C/EBP!–
Mediated Growth Arrest of Cells 
 
TCERG1 is a transcription elongation factor, shown to interact with both RNA 
polymerase II and splicing factor 1, suggesting that transcription and splicing events may be 
coupled (Carty et al., 2000; Goldstrohm et al., 2001).  Recently, TCERG1 was identified as an 
interactor with C/EBP! using a yeast two-hybrid screening approach (McFie et al., 2006).  
Using gene reporter assays, TCERG1 was also found to inhibit C/EBP! transcriptional activity.  
In addition, TCERG1 was found to inhibit the growth arrest function of C/EBP! in cultured 
cells.  Finally, results using a TCERG1 truncation mutant containing only the carboxy-terminus 
indicate that this domain does not contain the region(s) important for mediating this activity.  
Collectively, these data suggested that motifs found in the amino-terminal domain of TCERG1 
may be required for interaction and inhibition of C/EBP!-mediated transcriptional and growth 
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arrest activities (McFie et al., 2006).  However, it was unknown if the interaction and functional 
domains of TCERG1 lie in the same or different domain(s). 
In order to map the region(s) within TCERG1 responsible for inhibiting C/EBP! growth 
arrest activity, several TCERG1 truncation mutants were constructed to examine the functional 
ability of different domains to reverse cells under growth arrest (Figure 6 and 7).  Based on the 
data collected, the intact amino-terminal domain of TCERG1 was sufficient to reverse growth-
arrested COS7 cells.  This conclusion was supported by results obtained with several TCERG1 
truncation mutants.  First, a mutant lacking the entire amino-terminal region, TCERG1 641-
1098, was unable to reverse C/EBP!-mediated growth arrest of COS7 cells, similar to results 
reported previously (McFie et al., 2006).  Second, TCERG1 32-668, consisting of the intact 
amino-terminal domain, was sufficient to inhibit the growth arrest activity of C/EBP!.  Lastly, 
results from analysis of two additional TCERG1 mutants containing truncations in the amino-
terminal domain, TCERG1 32-293 and 281-1098, had significantly reduced ability to reverse 
growth arrest of cells.  Therefore, one could speculate that TCERG1 32-293 and 281-1098 are 
missing important functional motifs that are required to work together in order to achieve 
inhibition of C/EBP! activity.  Analysis of the amino acid sequence for both truncation mutants 
revealed that each was missing different WW domains.  Interestingly, results obtained from a 
study examining the involvement of different domains in TCERG1-mediated transcriptional 
repression show that WW1 and WW2 domains together are sufficient for repression of the !4-
integrin promoter (Goldstrohm et al., 2001).  This conclusion was supported by data from 
reporter assays using TCERG1 mutants with different combinations of deletions or mutations 
of critical residues found within each WW domain.  Additionally, data from Far-Western 
analyses identified pre-mRNA splicing factor SF1, which also functions as a transcriptional 
repressor (Zhang and Childs, 1998), as a TCERG1 WW-interacting protein.  Moreover, WW1 
and WW2 of TCERG1, but not WW3, was shown to specifically interact with SF1 by co-
immunoprecipitation studies using TCERG1 mutants consisting of individual WW domains.  
These data were also confirmed by Far-Western analyses using probes constructed from WW 1-
3 of TCERG1, of which the first two were found to interact with SF1 (Goldstrohm et al., 2001). 
It has been well established that many WW-containing proteins require multiple weak 
interactions for full biological function and that these domains have different binding affinities 
(Macias et al., 2002).  Generally, these interactions function in a co-operative manner to 
 69 
stabilize binding with its ligand, particularly when the protein or its ligand is large.  Therefore, 
based on the evidence collected here, it is reasonable to speculate that TCERG1-mediated 
inhibition of growth-arrested cells by C/EBP! may occur as a result of interactions with 
C/EBP! via multiple WW domains in the amino-terminal region of TCERG1.  Finally, WW-
domains are characterized by the binding of short proline-rich motifs that have been categorized 
into four classes based on the minimal consensus sequences they bind: PPxY, PPLP, PPR, and 
phospho-S/TP, respectively, where “x” denotes any amino acid (Sudol et al., 1995; Espanel and 
Sudol, 1999; Bedford et al., 2000; Sudol and Hunter, 2000).  In fact, C/EBP! has one 
characterized poly-proline motif (Nerlov and Ziff, 1994), and upon further inspection of the 
entire amino acid sequence of C/EBP! (Landschulz et al., 1988a; Lincoln et al., 1994; Rattus 
norvegicus: Accession number P05554), I have identified six other proline-enriched sequences 
that could serve as WW-ligand binding motifs (Figure 16).  Thus, there are several regions 
within C/EBP! that could serve as TCERG1 WW-interacting sequences that could mediate 
interaction and subsequent inhibition of C/EBP! activity. 
 
 
5.2  Characterization of TCERG1 and C/EBP! Spatial Distribution in COS7 and 
HEK293T Cells 
 
Subnuclear compartments, or nuclear bodies, have been identified and classified based 
on function, pattern of distribution and their respective molecular components (Matera, 1999; 
Misteli, 2001; Wang et al., 2002b).  These subnuclear compartments can act as storage sites for 
specific factors and/or assembly stations for transcriptional, splicing, and recycling purposes.  
Several lines of evidence have demonstrated that splicing factors have the exceptional ability to 
translocate from specific areas and become concentrated at sites of active transcription (Fu and 
Maniatis, 1990; Bregman et al., 1995; Misteli et al., 1997; Melcak et al., 2000; Mintz and 
Spector, 2000; Phair and Misteli, 2000; Carmo-Fonseca, 2002; Gorski et al., 2006).  Based on 
these data, it was hypothesized that a connection between subnuclear localization of TCERG1 
and C/EBP! and the inhibition of C/EBP!-mediated activity. 
To date, there has only been one study examining the subnuclear localization of 
TCERG1.  These studies were conducted in HeLa cells and IMR90 human fibroblasts
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Figure 16.  Putative TCERG1 WW-Binding Motifs in C/EBP!. 
WW domains bind to proline rich motifs classified by different ligand consensus sequences.  
Four classes of consensus sequences have been identified: PPxY, PPLP, [P]-PR and [phospho-
S/T]P, respectively, where X denotes any amino acid (Espanel and Sudol, 1999; Bedford et al., 
2000; Sudol and Hunter, 2000).  Seven putative proline-rich motifs (highlighted in grey) can be 
identified throughout the amino acid sequence of C/EBP! that may serve as TCERG1 WW-
binding ligands.  C/EBP!, Rattus norvegicus: Accession number P05554. 
 
 
(Sanchez-Alvarez et al., 2006).  Therefore, in this study, it was necessary to characterize the 
spatial distribution of TCERG1 in both COS7 and HEK293T cells prior to further analysis.  In 
studies performed by Sanchez-Alvarez et al. (2006), TCERG1 primarily localized within 
domains termed splicing factor-rich nuclear speckles (Hall et al., 2006), designated by the 
many splicing factors that reside in these domains.  In COS7 and HEK293T cells, TCERG1 32-
1098 also localized within nuclear speckles, verified by immunofluorescent detection of SC35, 
a nuclear speckle marker (Fu and Maniatis, 1990).  Collectively, localization studies performed 
in several cell lines suggest that TCERG1 strongly associates with splicing factor-rich nuclear 
speckles (Sanchez-Alvarez et al., 2006) and thus, is an intrinsic property of TCERG1.  Based 
on the results from several studies examining components of nuclear speckles (Mintz and 
Spector, 2000; Misteli, 2001; Carmo-Fonseca, 2002; Iborra and Cook, 2002; Gorski et al., 
2006; Hall et al., 2006), these subnuclear structures likely serve as reservoirs from which 
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splicing factors, and possibly TCERG1, can be assembled into protein complexes or can be 
recruited to other domains found within the nucleus. 
During the co-localization analysis of TCERG1 and C/EBP!, it was apparent that 
C/EBP! adopted several different subnuclear localization patterns.  Upon reviewing the 
literature, various studies examining the nuclear localization pattern of several nuclear factors 
involved in chromatin remodeling or cell cycle regulation have revealed different patterns of 
occupancy determined by the stage of the cell cycle (Rountree et al., 2000; Bozhenok et al., 
2002).  However, the aforementioned studies used chemicals to synchronize cells, which were 
then released from certain stages of cellular arrest, allowing researchers to follow changes in 
protein localization throughout the cell cycle.  In the studies presented here, cells were not 
subjected to chemicals to synchronize cells or cause cellular arrest.  The possibility of 
synchronizing the cells by chemical means was explored but from repeated experiments it was 
concluded that the cells examined were not very robust and were sensitive to this type of 
treatment.  Moreover, an interesting study examining the localization pattern of CBP in 
transiently transfected cells and untransfected cells expressing endogenous CBP revealed that 
different cell lines and conditions compartmentalize CBP into different nuclear patterns 
(LaMorte et al., 1998).  In certain cell lines, such as Chinese hamster ovary cells and COS-1 
cells, CBP localizes in a dispersed reticular pattern and is found concentrated within 
promyelocytic leukemia nuclear bodies, whereas in HEK293, hepatocellular carcinoma-G2 and 
human epithelial cervical cancer cells, CBP localizes only in a dispersed pattern.  Thus, it is 
possible that cells can adapt to the overexpression of a protein by dysregulating the localization 
of the protein, such as CBP to promyelocytic leukemia nuclear bodies.  However, the primary 
localization pattern of C/EBP! in the majority of COS7 and HEK293T cells was consistent, 
suggesting that these sites of occupancy were the most stable. 
Upon assessing the subnuclear distribution of C/EBP! in COS7 and HEK293T cells, the 
pattern of C/EBP! compartmentalization observed between these two cell types appeared 
noticeably different.  Although several patterns of localization were visualized in COS7 cells, 
only one pattern was consistent in HEK293T cells.  Previous studies examining the spatial 
distribution of C/EBP! have shown that C/EBP! localizes to peri-centromeric regions in mouse 
GHTF1-5 progenitor pituitary cells and 3T3-L1 adipocytes (Tang and Lane, 1999; Schaufele et 
al., 2001, 2003; Zhang et al., 2001; Liu et al., 2002, 2007).  A recent study provided strong 
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evidence to support that C/EBP! binds to mouse major !-satellite DNA repeats situated near 
peri-centromeric heterochromatin (Liu et al., 2007).  However, this pattern of localization has 
not been described in cell lines from other species.  This could explain the apparent differences 
in the localization patterns of C/EBP! in the cell types examined in this study.  In addition, 
various post-translational modifications may have cell-type specific responses that may affect 
the subnuclear localization of C/EBP!.  In studies examining the localization of C/EBP! and 
C/EBP! during 3T3-L1 pre-adipocyte differentiation, it has been observed that both isoforms 
adopt distinct patterns of subnuclear localization in a phosphorylation-dependent manner, a 
process which occurs within hours of their expression (Tang and Lane, 1999).  Moreover, 
studies have shown that growth hormone affects the nuclear distribution of C/EBP!, resulting 
from phosphorylation by mitogen-activated protein kinase.  Therefore, it is feasible that in early 
stages of C/EBP! expression, certain post-translational events might be required for proper 
localization of C/EBP! within the nuclei of COS7 and HEK293T cells.  Likewise, certain 
functional motifs found within C/EBP! may play a role in its subnuclear localization in a cell 
type-specific manner.  Interestingly, it has been demonstrated that the (QA)38 repeat domain of 
TCERG1 has been implicated in the nuclear restriction of TCERG1 in rat striatal cells (Arango 
et al., 2006).  However, this domain appears to play no such role in either COS7 or HEK293T 
cells based on the observation that TCERG1 281-1098, which lacks the QA repeat, exhibited 
proper nuclear restriction and distribution (see Figure 12A and 14A).  Therefore, we cannot 
conclusively confirm that C/EBP! binds to peri-centromeric regions in cell lines of human and 
African green monkey origin and that localization of C/EBP! and -! to peri-centromeric 
regions may be restricted to murine-derived cell types.  Further studies using heterochromatin 
markers such as heterochromatin protein 1-! and major centromere auto-antigen B or DNA-
binding stains such as 4’,6-diamidino-2-phenylindole or Hoechst stain are needed in order to 
show the heterochromatin-associated occupancy of C/EBP! in these cells types.  Finally, it is 
important to note that the C/EBP!-EGFP fusion protein used in the localization studies reported 
in this thesis has been shown to retain transcriptional activity in GHFT1-5 cells (Schaufele et 
al., 2001) as well as growth arrest activity reported here.  This strongly suggests that the fusion 
protein compartmentalized appropriately, since an altered compartmentalization might be 
expected to alter its activity. 
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5.3  Link Between TCERG1-Mediated Inhibition of C/EBP! Growth Arrest Activity and 
Subnuclear Localization 
 
Based on the data collected from growth arrest assays and co-localization studies, the 
intact amino-terminal domain of TCERG1 appears to be involved in both mediating an 
inhibitory response to growth arrest and is sufficient for co-localization with C/EBP!.  This is 
supported by the evidence gathered from studies with TCERG1 32-668, which was able to 
reverse growth arrest to levels similar to 32-1098 and to completely co-localize with C/EBP!, 
despite its different initial pattern of localization. 
 During the co-localization studies between TCERG1 32-1098 and C/EBP!, it was 
intriguing to find that TCERG1 32-1098 completely co-localized with C/EBP!.  This striking 
translocation of TCERG1 32-1098 to sites occupied by C/EBP! provided insight into a 
potential mechanism to explain how TCERG1 inhibits the activities of C/EBP!, leading us to 
consider the less-characterized alternative methods of inhibition involving subnuclear retention.  
The complete co-localization observed between TCERG1 and C/EBP! may be a result of direct 
interaction between these two proteins (McFie et al., 2006) and this interaction alone could be 
responsible for the inhibition of C/EBP! activity.  The formation of inactive TCERG1/C/EBP! 
complexes could invariably prevent the access of various co-factors involved in recruiting 
C/EBP! to functional compartments and/or activating C/EBP! activity.  Furthermore, results 
from co-localization studies using TCERG1 truncation mutants suggest that the intact amino-
terminal domain of TCERG1 is necessary to co-localize with C/EBP! within inactive nuclear 
storage compartments.  This was further emphasized by the results obtained for TCERG1 641-
1098, a mutant unable to interact with or function as an inhibitor of C/EBP! activity (McFie et 
al., 2006).  TCERG1 641-1098, whose amino-terminal domain was deleted, localized to areas 
within the COS7 and HEK293T cells distinct from C/EBP! (see Figure 12C and 14C).  
Therefore, the complete lack of inhibitory activity toward C/EBP! could be explained, in part, 
by the fact that this mutant no longer has the functional domains necessary to interact with or 
co-localize with C/EBP!.  Finally, TCERG1 32-293 and 281-1098, both unable to significantly 
reverse growth arrest, also failed to co-localize completely with C/EBP! (Figure 6B, 12D, E 
and 14D, E).  However, the partial co-localization of both with C/EBP!, observed by the faint 
regions of overlap, may be a result of limited interaction between TCERG1 and C/EBP! 
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contributed by amino-terminal functional motifs retained by each mutant.  Research has shown 
that multiple weak interactions via aromatic amino acids found in the binding pockets of WW1 
and WW2, but not WW3 are required for repression of the !4-integrin promoter (Goldstrohm et 
al., 2001).  Although that study focused on the effect of TCERG1 on transcriptional activity, 
these domains may be involved in mediating interactions with C/EBP! resulting in the 
inhibition of its anti-proliferative and transcriptional activity.  Therefore, TCERG1 mutants 
missing either of these domains, such as the TCERG1 32-293 and 281-1098 mutants, which 
lack WW1 and WW2, respectively, may possess limited or unstable interactions with C/EBP! 
and thus reduced or limited ability to reverse growth arrest of cultured cells.  However, the 
contribution of multiple interactions may not be limited to WW1 and WW2 since the (QA)38 
repeat was retained in several of the mutants studied.  Although no biological role has been 
assigned to this unique repeat domain, it cannot be ruled out as a potential participant in 
TCERG1 inhibitory activity.  Additionally, interactions with other nuclear factors may be 
required to assist in the translocation of TCERG1 to sites occupied by C/EBP!.  Finally, the 
alteration in TCERG1 localization is likely a biologically relevant response since these 
observations could be demonstrated in different cell lines and occurs specifically in response to 
C/EBP!.  Together, these data support the hypothesis that the intact amino-terminal domain of 
TCERG1 mediates the inhibition of C/EBP! activity using a general retention mechanism and 
may involve the additive effects of WW1 and WW2 of TCERG1. 
 
 
5.4  TCERG1 Specifically Co-localizes with C/EBP! But Not C/EBP" 
 
It was recently shown that TCERG1 has the ability to inhibit the transcriptional activity 
of another C/EBP isoform, C/EBP" (McFie et al., 2006).  Therefore, it was questioned if the 
mechanism by which this occurs may involve nuclear retention of C/EBP" as well.  Thus, co-
localization studies were performed in COS7 and HEK293T cells and observed for alterations 
in TCERG1 subnuclear distribution upon the ectopic expression of C/EBP".  Results indicated 
there was no relationship between inhibition of C/EBP" and co-localization with TCERG1 in 
both cell types, as no apparent changes were detected in the compartmentalization of TCERG1.  
These findings were unexpected for a couple of reasons.  First, previous studies suggested that 
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these two proteins interact and that TCERG1 inhibits the activity of C/EBP! (McFie et al., 
2006).  Secondly, C/EBP" adopts a subnuclear localization pattern analogous to C/EBP! in the 
cell lines studied, therefore, one might expect TCERG1 and C/EBP" to co-localize if TCERG1-
mediated inhibition involves a retention mechanism.  This marked difference between C/EBP! 
and C/EBP" in relation to the localization of TCERG1 creates the possibility that TCERG1-
mediated inhibition with respect to each isoform occurs by a different mechanism.  Although 
the functions of C/EBP isoforms often overlap, different forms of regulation by TCERG1 may 
be induced in response to conditions marked by the expression of different C/EBP isoforms.  
Alternatively, in conditions where both C/EBP isoforms are expressed, C/EBP!-mediated 
translocation of TCERG1 to sites occupied by C/EBP! may allow TCERG1 to interact with and 
inhibit C/EBP" in a C/EBP!-dependent manner.  Identification of co-factors that may be 
directly or indirecty involved in the inhibition of C/EBP" transcriptional activity by TCERG1 
may provide insight into an alternative mechanism by which this down-regulation is achieved. 
 
 
5.5  Model for the Mechanism By Which TCERG1 Inhibits the Activities of C/EBP! 
 
The ordered nature of the nucleus is extremely complex and thus requires many levels 
of regulation and co-ordination between various nuclear factors in order for specific events to 
occur.  Several possibilities exist for mechanisms that regulate the flux of nuclear body 
components to and away from intranuclear sites.  These activities may be controlled by direct 
interaction, post-translational modification, altering the rate of mobility, and/or sequestration 
with or without the assistance of other nuclear factors (Carmo-Fonseca, 2002; Iborra and Cook, 
2002; Corry and Underhill, 2005).  Nuclear factors may also be negatively regulated by 
mechanisms involving the retention of proteins within certain subnuclear compartments, 
thereby altering access of co-factors or by preventing the ability of the protein to translocate to 
sites where it is functionally active.  As such, mounting evidence suggests that TCERG1 
inhibits the activities of C/EBP! through a subnuclear retention mechanism. 
In recent years, our laboratory has provided compelling evidence for a new biological 
role for TCERG1 with respect to inhibition of the activities of a well-characterized transcription 
factor, C/EBP! (this study and McFie et al., 2006).  What makes TCERG1 unique is that it 
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inhibits two very different activities of C/EBP!.  Moreover, these activities are found within 
different domains of C/EBP!.  Based on the studies presented here, I have proposed a model 
where TCERG1 inhibits all of the activities of C/EBP! by interacting with and retaining 
C/EBP! within inactive subnuclear storage sites (Figure 17). C/EBP! is consequently 
prohibited from redistributing to sites of active transcription or from interacting with other 
nuclear factors that may be involved in the translocation or activation of C/EBP! activity.  
Whether this inhibition is achieved by direct interaction between TCERG1 and C/EBP! or by 
an indirect mechanism involving other regulatory molecules recruited to or found near sites 
associated with C/EBP! remains unresolved.  Therefore, it would be important to identify 
factors that may assist in the trafficking process responsible for the redistribution of TCERG1 
to C/EBP!-containing regions.  How is TCERG1 released from nuclear speckles allowing for 
its localization with C/EBP!?  Does it result from random interactions between C/EBP! and 
free moving TCERG1 molecules not associated with nuclear speckles or is it a coordinated 
event in response to some type of signalling event?  Several recent studies have confirmed the 
ability of nuclear factors to traverse the nucleus (Fu and Maniatis, 1990; Misteli et al., 1997; 
Phair and Misteli, 2000; Gorski et al., 2006; Kaiser et al., 2008; Misteli, 2008b) However, it 
has not been well documented how this mobility is achieved beyond the influence of 
extracellular stimuli or as a result of post-translational modification.  Preserving cells at various 
time points or using real-time live cell imaging to visualize protein movement should provide 
insight into the pathway TCERG1 travels to become co-localized with C/EBP!. 
While the studies presented here focus on the growth arrest activity of C/EBP!, future studies 
could be expanded to incorporate the ability of TCERG1 to inhibit transcriptional activities of 
C/EBP! in the context of subnuclear localization.  If TCERG1-mediated inhibition of C/EBP! 
transcriptional activity by means of a subnuclear retention mechanism can be verified, the 
discovery of this type of global regulation is of significant importance.  To date, evidence for a 
retention mechanism resulting in the simultaneous inhibition of multiple activities of a 
transcription factor has yet to be described elsewhere.  Thus, these findings present us with a 
unique opportunity to investigate the relationship between the regulation of transcription factor 
activity and subnuclear structure and, therefore, will be immensely beneficial to our 
understanding of all aspects of cellular regulation. 
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Figure 17.  Proposed Model for the Mechanism By Which TCERG1 Inhibits the Activities 
of C/EBP!. 
A simplified eukaryotic cell nucleus is shown containing nuclear components involved in 
TCERG1-mediated inhibition of C/EBP! activity. C/EBP! (green square) is concentrated in 
globular domains associated near inactive heterochromatin (Liu et al., 2007).  Co-factors, CBP 
(purple diamond) and TBP (aqua triangle), have been shown to associate with C/EBP! at these 
subnuclear domains by an unknown mechanism (Schaufele et al., 2001).  TCERG1 (red circle) 
is generally found within splicing factor-rich nuclear speckles (Sanchez-Alvarez et al., 2006) 
but becomes associated with C/EBP! when co-expressed in cultured cells.  The redistribution 
of TCERG1 to nuclear subcompartments occupied by C/EBP! results in the inhibition of 
C/EBP!-mediated activity.  The association between TCERG1 and C/EBP! results in the 
inhibition of C/EBP! growth arrest activity by blocking interaction between C/EBP! and 
critical components of cell cycle progression, cdk2 and cdk4 (Wang et al., 2001).  The 
transcriptional activity of C/EBP! is downregulated by TCERG1 by preventing the formation 
of an active transcriptional complex between C/EBP! and transcriptional co-activators such as 
CBP and TBP.  The resulting complex may be retained within inactive C/EBP! storage sites 
restricting its access to transcription factories, thereby providing an additional level of negative 
regulation.  The validity of this model remains to be tested and requires further study to verify 
these hypotheses.  Several factors such as cell state, signaling events and association and/or 
function with other proteins may be required for the redistribution of the nuclear factors 
discussed. 
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5.6  Future Directions 
 
The collective results obtained from growth arrest and co-localization studies strongly 
implicate the amino-terminal region of TCERG1 as the key domain responsible for the 
inhibition of C/EBP!-mediated growth arrest activity.  An intact amino-terminal domain of 
TCERG1 is also required for co-localization with C/EBP!.  More specifically, WW1 and WW2 
are the likely candidates involved in mediating these effects.  If interaction between C/EBP! 
and TCERG1 via WW domains can be validated, it is probable that the inhibition mediated by 
TCERG1 results from its interaction with C/EBP!.  Further studies are needed to examine the 
involvement of TCERG1 WW domains in mediating the inhibition of C/EBP! activity.  
TCERG1 mutants containing different combinations or entire deletions of individual WW 
domains could be generated and tested for their ability to interact with C/EBP! and restore the 
proliferative capacity of cell under growth arrest caused by C/EBP!.  Additionally, the 
involvement of WW1 and WW2 could be addressed by mutating key residues within each WW 
domain required for ligand binding, which could then be assessed using various functional and 
protein interaction assays.  Furthermore, examination is necessary to test each mutant in the 
context of TCERG1-mediated inhibition of C/EBP! transcriptional activity to determine if WW 
domains are involved.  If indeed interaction between C/EBP! and the WW domains is a 
prerequisite for the inhibition of C/EBP! transcriptional activity, then these results in 
combination with those gathered from this study offer compelling evidence to support a model 
where TCERG1 exerts its inhibitory activity through a general mechanism involving subnuclear 
retention resulting from interactions provided by WW1 and WW2.  Finally, although the data 
point toward the involvement of the first two WW domains in mediating the inhibitory activity 
of TCERG1, the potential role of the (QA)38 repeat domain cannot be ignored.  To date, no 
biological function has been given to this domain.  Moreover, in studies presented by 
Goldstrohm et al. (2001), the impact of the (QA)38 repeat on TCERG1-mediated repression of 
transcriptional activity was not addressed.  Hence, this domain should be considered in future 
experiments to determine the requirements of the (QA)38 repeat in TCERG1 inhibitory activity 
and/or interaction with C/EBP!.  Finally, in vitro assays provide several limitations when 
assaying cells expressing C/EBP!, which is generally tightly controlled and limited to 
differentiated cell types.  Additionally, the quantity of plasmid DNA expressing C/EBP! must 
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be low to prevent apoptosis (data not shown).  Since all co-localization studies were performed 
in cell lines that do not express endogenous C/EBP!, additional studies should be performed in 
cell lines that can be induced to express endogenous C/EBP!, such as pre-adipocytes or stable 
cell lines with an on/off expression system.  This would allow the examination of co-
localization between TCERG1 and C/EBP! in situations where expression of C/EBP! can be 
controlled, mimicking a more natural environment.  Moreover, it would be beneficial to repeat 
co-localization studies in each cell line with the detection of endogenous TCERG1 by 
immunofluorescence to substantiate the marked translocation of TCERG1 to C/EBP!-
containing subnuclear compartments.  Should results obtained from conditions examining the 
localization of endogenous protein be similar to those reported herein, then the data collected 
using fluorescent fusion proteins to TCERG1 and C/EBP! accurately reflects the physiological 
behaviour of the native protein. 
Although extensive research has been able to identify numerous nuclear bodies (Matera, 
1999; Misteli, 2001; Wang et al., 2002b; Iborra et al., 2003), none seem to fit the morphology 
or characterization of the sites occupied by C/EBP! in COS7 and HEK293T cells and at peri-
centromeric regions in murine cell types.  Thus, it would be of interest to determine the 
functional purpose of C/EBP! subnuclear localization, why it localizes to particular sites, and 
to find other factors that may be associated with these nuclear bodies.  It has been demonstrated 
that C/EBP! localizes to peri-centromeric regions in a phosphorylation-dependent manner in 
3T3-L1 pre-adipocytes (Tang and Lane, 1999).  Thus, the role of phosphorylation in the 
localization of C/EBP! in COS7 and HEK293T cells could be examined by mutating 
key/susceptible phosphorylation sites within C/EBP! (reviewed in Khanna-Gupta, 2008) which 
can then be assessed for alterations in subnuclear compartmentalization.  Studies in GHFT1-5 
cells indicate that peri-centromeric localization of C/EBP! also requires the carboxy-terminal 
leucine zipper region, because when deleted, C/EBP! becomes dispersed throughout the 
nucleus (Liu et al., 2002).  Likewise, this study also demonstrates that a single amino acid 
substitution at position 296 from valine to alanine, causes C/EBP! to become dispersed in the 
nucleoplasm and no longer associate with peri-centromeric regions.  Collectively, these 
findings provide a foundation from which one can explore the requirement of C/EBP! 
localization to peri-centromeric regions for TCERG1-mediated inhibition to occur.  However, 
studies looking at the subnuclear localization of C/EBP! thus far have been limited to murine 
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cell types (Tang and Lane, 1999; Schaufele et al., 2001, 2003; Wang et al., 2001; Zhang et al., 
2001; Liu et al., 2002; Day et al., 2003; Enwright et al., 2003; Demarco et al., 2006).  
Therefore, one can only extrapolate so much when comparing to studies conducted in cell types 
of other species.  Thus, the necessity for proper characterization of the specific subnuclear 
localization patterns of C/EBP! observed in COS7 and HEK293T cells is critical for 
understanding the relationship between function and subnuclear residency. 
To date, there has only been one study showing the ability of C/EBP! to recruit 
transcriptional co-activators, CBP and TBP, to peri-centromeric regions in mouse progenitor 
pituitary GHTF1-5 cells (Schaufele et al., 2001).  Interestingly, our studies have suggested that 
TCERG1 does not interact with either of these co-factors (McFie et al., 2006).  It would be 
intriguing to investigate the co-localization of C/EBP! and CBP or TBP in the presence of 
TCERG1.  Likewise, C/EBP! directly interacts with cdk2 and cdk4 to cause growth arrest 
(Wang et al., 2001).  Therefore, the localization of each with C/EBP! in the presence of 
TCERG1 could be examined to determine if cdk2 and cdk4 remain associated with C/EBP!.  It 
can be anticipated that the interaction and co-localization between C/EBP! and TCERG1 would 
prevent proper binding of the aforementioned co-factors with C/EBP!, thus resulting in the 
inhibition of C/EBP!-mediated activity.  Further insight into the inhibition of growth arrest by 
TCERG1 could also be gained by using a C/EBP! Ser193Ala mutant whose growth arrest 
activity was not only abolished but resulted in accelerated proliferation of hepatoma cells 
(Wang and Timchenko, 2005).  This study also demonstrated that the interaction between 
C/EBP! and Rb results in cellular arrest, hence, co-localization between Rb and C/EBP! may 
be altered upon the overexpression of TCERG1 thereby releasing cells from growth arrest.  
However, the subnuclear distribution of C/EBP! with mutations affecting its activity must first 
be addressed before examining its co-localization with TCERG1. 
Although there appears to be a link between TCERG1 inhibitory activity of C/EBP!-
mediated growth arrest and subnuclear localization, these studies must be expanded to 
incorporate the inhibition of C/EBP! transcriptional activity.  Does C/EBP! require 
transcriptional activity for redistribution of TCERG1 to sites occupied by C/EBP!?  This could 
be tested by altering the transcriptional activity of C/EBP! by deleting important domains 
required for this activity or by mutating key amino acids within these domains.  Alternatively, 
Liu et al. (2002) have shown that when EGFP is fused to the amino terminus of C/EBP!, it no 
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longer possesses transcriptional activity.  Therefore, alterations in the localization of TCERG1 
could be analyzed upon expression of the various C/EBP! mutants lacking transcriptional 
activity to determine if this activity is necessary.  Moreover, a recent study presents data 
supporting the ability of pituitary-specific transcription factor Pit-1 to recruit C/EBP! to 
intranuclear sites occupied by Pit-1 (Enwright et al., 2003).  It would be interesting to examine 
the localization of TCERG1 in the context of GHFT1-5 pituitary cells expressing Pit-1.  Would 
TCERG1 retain C/EBP! within peri-centromeric regions thereby inhibiting the activation of 
genes specifically co-regulated by Pit-1 and C/EBP!?  Finally, identifying the TCERG1 
interaction domain within C/EBP! would be pivotal in order to establish a definitive 
relationship between subnuclear compartmentalization and inhibition of C/EBP!-mediated 
activity through interactions with TCERG1 by performing co-localization studies where the 
interaction between TCERG1 and C/EBP! is abolished. 
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